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The HPV vaccine has been proven as a safe and effective method for preventing cervical
cancer. However, the HPV vaccine coverage rate in the U.S. is suboptimal. Various
interventions have been implemented to improve HPV vaccine coverage. However, evidence
of the cost-effectiveness of HPV vaccine promotion interventions is lacking. We conducted an
economic evaluation to assess HPV vaccine promotion interventions of cervical cancer in the
U.S. Firstly, a systematic review was conducted to review evidence on interventions aimed at
increasing HPV vaccine coverage and to summarize the cost and effectiveness of these
interventions. We included 56 HPV vaccine promotion studies in the review. Intervention
approaches used to promote the HPV vaccine included patient reminder and recall systems
(N=12), patient education (N=16), provider assessment and feedback (N=1), provider reminder
(N=2), reducing out-of-pocket costs (N=3), school-based vaccine programs (N=4), vaccination
requirements for school attendance (N=3), and intervention combinations (N=14). We also
identified 7 studies that reported intervention costs. Most interventions significantly increased
HPV vaccine rates using varied approaches across populations and settings, and with modest
cost. The cost-effectiveness analysis is needed to determine which intervention type is the most
cost-effective.

Secondly, we assessed the cost-effectiveness of several U.S. HPV vaccine promotion
interventions versus current practice. Interventions of patient reminder and recall system,
patient education, provider reminders, reducing patient out-of-pocket costs, school-based
vaccine programs, and community-based intervention combinations were included in the
evaluation. We found that patient reminder and recall system is the most cost-effective HPV
vaccine promotion intervention. The cost per additional individual that completed HPV
vaccine series (ICER) was $238. When the intervention effectiveness was measured as the
percentage change of receiving at least one dose HPV vaccine, the ICER for the patient
reminder and recall system was $107. A cost-utility analysis was conducted to assess HPV
vaccine promotion interventions on cervical cancer in the U.S. The study shows that
implementing patient recall and reminder system is the most cost-effective intervention for
cervical cancer. Compared with current practice, patient recall and reminder system is costsaving since the cost is lower and yields a better health outcome. Decision-makers need to
consider the applicability of interventions and budgets for implementing the interventions.
Social and political issues need to be discussed by stakeholder groups before HPV vaccine
promotion interventions are successfully implemented.
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BACKGROUND
In 2019, nearly 13,000 women in the United States were newly diagnosed with cervical
cancer (0.7% of all new cases of female cancers) and more than 4,000 women (0.7% of all
cancer deaths) died from the disease.1 The majority of cervical cancers are caused by human
papillomavirus (HPV). Anyone who has ever been sexually active has a chance of being
infected with HPV. In the U.S., more than 80% of sexually active individuals are expected to
become infected with HPV at some point in their lives.2 This highlights the importance on
preventing the HPV infections in the US.
The HPV vaccine has been proven as a safe and effective method for preventing HPV
transmission. However, the vaccine’s coverage rate in the U.S. has been relatively low
compared to coverage in other developed countries. According to recent data estimates, the
up-to-date HVP vaccine coverage in 2017 was 48.6% among adolescents aged 13-17 years. 3
This coverage is far below the CDC’s Healthy People target of 80% coverage by 2020. In
comparison to 2017 coverage rates in other developed countries, the HPV vaccine coverage
among females aged 12-13 years was 90% in the United Kingdom 4 and 85% for females at age
15 in Australia.5 Implementing HPV vaccine promotion interventions is the accepted approach
to increasing vaccination coverage. However, because there are many different ways to
implement intervention, it is hard to determine which intervention method is the most costeffective for increasing that coverage. A systematic review that summarizes and quantifies the
impact of the current published HPV intervention methods can help enable healthcare
professionals to evaluate the entire spectrum of interventions.
1

Previous studies have focused on the economic evaluations of HPV vaccine programs
in relation to preventing cervical cancer.6 However, those studies have typically failed to
include the resources consumed by the interventions themselves, which may have biased the
estimates of HPV vaccine program’s health and economic impacts. To more realistically reflect
the overall impacts of HPV vaccination programs, the costs of resources involved in the
intervention strategies designed to improve coverage rates should also be incorporated in the
economic evaluation research. For this present study, a systematic literature review was
conducted to identify the cost-effectiveness of different HPV vaccine promotion interventions.
We then incorporated synthesized evidence about intervention cost and effectiveness into the
HPV vaccine economic evaluations to understand their impacts on HPV transmission
preventions.
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Epidemiology of cervical cancer
From the latest data released by the Centers for Disease Control and Prevention (CDC), the
incidence of cervical cancer in the U.S. was 7.7 per 100,000 women in 2016. The mortality
rate of cervical cancer was 155.9 per 100,000 women in 2016.7 Both the incidence and
mortality rate of cervical cancer have decreased over time (Figure 1). 7 This decline has resulted
mainly due to cervical cancer screening of the majority of women in the U.S. In 2015,
approximately 80% of women aged 21-65 years old received cervical cancer screening (Figure
2).8 Because of the screening, the cancer can be found earlier and patients can be treated in the
early stage.
Although both incidence and mortality rates of cervical cancer were declined among women
diagnosed with cervical cancer from 2010 to 2015, more than 72% of them were younger than
60 years old. We found that the prevalent age of cervical cancer is younger, compared with top
ranking female cancers including breast and ovary cancer. From 2010 to 2015, the percentage
of women younger than 60 years old diagnosed with breast cancer and ovary cancer were
37.62% and 44.80% in the US, respectively (Figure 3) 7. This highlights the importance of
works in cervical cancer prevention.
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Figure 1. Incidence and mortality of cervical cancer from 1999 to 2016 in the U.S.
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Figure 2. Percentage of women aged 21-65 years old receiving cervical cancer screening from
2000-2015 in the U.S.
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Figure 3. Percentage of women diagnosed with cervical, breast and ovarian cancer in the U.S.
from 2010 to 2015
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HPV vaccine access, utilization and policy in the U.S.
The HPV vaccine was approved by the Food & Drug Administration (FDA) in 2006 and
recommended as standard coverage by enrolled health insurance plans, without increasing
consumer cost-sharing. For individuals lacking access to private insurance, the vaccine can be
covered through the following public-financed sections. 9,10
1.

Vaccines for Children (VFC) Program
The VFC is a federally-funded program that provides HPV vaccines through the CDC to
individuals younger than 19 years of age. Under the VFC program, there is no charge for
the HPV vaccine for eligible children including Medicaid eligibilities, uninsured or
underinsured individuals, and American Indians or Alaska Natives.

2.

Immunization Grant Program (Section 317)
Section 317 of the Public Health Service Act authorizes the federal government to
purchase vaccines for distribution. It extends HPV vaccine access to underinsured
children who are not eligible for coverage under the VFC and for uninsured adults.

3.

Medicaid
Individuals under age 21 who are enrolled in the Medicaid program are eligible for
Medicaid’s Early and Periodic Screening, Diagnostic and Treatment (EPSDT) coverage
for the HPV vaccination.

4.

Children’s Health Insurance Program (CHIP)
CHIP is intended to provide coverage for uninsured children in families whose income is
too high to qualify for Medicaid but who can not afford the private coverage. For children
who are not eligible for VFC, Medicaid CHIP is a possible source for HPV vaccine access.
6

In 2007 following the first year of its FDA approval, the HPV vaccine’s coverage rate was
5.9%; by 2018, the rate had increased to 53.7% (Figure 4).11–13 Compared to rates in other
developed countries including United Kingdom and Australia, HPV vaccine coverage in the
U.S. is relatively low. The 2018 HPV vaccine coverage rates were 83.8% (2-dose) among
females aged 13-14 years old in the United Kingdom.12 In Australia, the HPV vaccine
coverage among 15 years old females was 80.2% in 2017.13 Both countries offered free HPV
vaccines to males and females starting at age 12 years through national HPV vaccine programs.
In the U.S., policies for HPV vaccination vary by state. State-based policies for improving
HPV vaccination can be categorized as follows: 1) mandated vaccine for females; 2) mandated
vaccine for males; 3) public funding offered; 4) mandated private health-insurance coverage
of vaccine; 5) provided for vaccine-information delivery; 6) provided HPV-related awareness
campaign; 7) bill supporting voluntary vaccination; 8) political backlash and/or mandatereversal bill; and 9) others.14 Since the initial 2006 policy approval in the U.S., 28 states have
introduced bills regarding the HPV vaccine mandate to their legislatures, and three
jurisdictions now require HPV vaccines for school attendance: Virginia, Rhode Island, and the
District of Columbia. Most of the policy implementation across states has focused on
awareness campaigns, vaccine information, ensuring private coverage, and public funding. 14
Because each state has different policies toward HPV vaccination, the coverage rates also vary
by state. North Dakota had the highest HPV vaccine completion rate among girls aged 13-17
years in 2018 (52.8%), and Mississippi had the lowest vaccine coverage (23.4%) among stated
without school mandate requirements.11
7

While three states currently have a school mandate requirement for HPV vaccination, the
impact of the policy on uptake and completion is unknown. The National Immunization
Survey-Teen (NIS-Teen) data shows the 2018 HPV vaccine 3-dose coverage rates among
females aged 13-17 in Rhode Island, Virginia, and D.C. were 54.5%, 48.0%, and 58.3%,
respectively.11 We found that even with this HPV vaccine school entry requirement, the
coverage is far below the Health People target for 2020. Based on NIS-Teen data for 20092013, our study also found that states with school mandates did not have higher HPV vaccine
rates among females aged 13-17 years compared to states without school mandates. Provisions
for religious exception, personal belief exemptions, and liberal opt-outs to the HPV vaccination
may in fact weaken the school mandates impact.15 Since the impact between mandate
implementation and HPV vaccine coverage is not clear, implementing intervention programs
is a critical way to increase the HPV vaccine coverage.
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Figure 4. HPV vaccine coverage in USA, UK and Australia
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HPV vaccine promotion interventions in the U.S.
The Community Guide’s reports concluded the following interventions have been used to
promote immunization rates, including patient reminder and recall systems, patient education,
provider assessment and feedback, provider reminders, vaccination requirements for school
attendance, vaccination programs in schools, reducing out-of-pocket costs, standing orders,
immunization information systems and multiple component interventions (interventions
implemented in combination involved more than two interventions). However, conclusions
about the most effective HPV vaccine promotions were heterogeneous across the studies. One
study found that population-based vaccination strategies that consistently reached the greatest
number of participants, such as school-based vaccination programs were the most successful
at reaching a high HPV vaccine uptake rate.16 Another systematic review suggests that those
interventions designed in combination for both the community and the provider have been the
most effective in terms of increasing the uptake rate.17 A systematic review that identified
evidence of educational interventions of the HPV vaccine concluded there is no strong
evidence to recommend any particular educational intervention to achieve high uptake rates. 18
Given these results, it’s clear additional studies of HPV vaccine intervention methods are
needed in order to identify the most effective approach.
Cost is also an important element when evaluating intervention methods. However, evidence
about the cost of HPV vaccine promotion intervention is limited. Most of the intervention
studies we reviewed did not report cost results for implementing the intervention. From those
studies which did, the units were heterogeneous across studies, making it difficult to compare
costs between and among different intervention approaches. For example, one study applying
10

the provider assessment and feedback approach reported the cost per child vaccinated. 19 In
another, the cost per vaccine administered in a school vaccination program was used. 20
Additional cost studies and synthesized results are needed to create the basis for a better
understanding.
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Economic evaluation for HPV vaccination in the U.S.
We reviewed published economic evaluation studies about HPV vaccine program which
showed consistently that HPV vaccine program is cost-effective in in preventing HPVassociated cancers, compared with currently standard programs. 6 Chesson et al. assessed the
cost-effectiveness of HPV vaccination in the U.S. of 12-year-old females. Their results show
that the HPV vaccine was more cost-effective at preventing cervical cancer compared with the
current screening policy. The estimated cost per quality-adjusted life year (QALY) ranged
from $3,906 to $14,723.21 Approximately 70% of cervical intraepithelial neoplasia (CIN) and
20% of cervical cancers were found to be preventable by implementing the HPV vaccine. In a
2007 study, Elbasha et al. assessed the epidemiologic consequences and cost-effectiveness of
HPV vaccination among 12-year-old females. They found the HPV vaccination was costeffective, with an incremental cost-effective ratio (ICER) averaging $4,666 per QALY
compared with no vaccination. They concluded that vaccinating girls younger than 12 could
reduce the incidence of genital warts (83%) and cervical cancer (78%) resulting from HPV
infections. Overall, HPV vaccination is cost-effective when compared with currently accepted
programs which prevent HPV-related outcomes.6
While HPV vaccination has been shown as a cost-effective method of cancer prevention,
our findings indicate that the majority of economic evaluations addressing HPV vaccination
have assumed an HPV vaccine coverage rate of up to 70%. For example, both Chesson et al.
and Elbasha et al. assumed the HPV 3-dose coverage increased linearly from 0% to 70% during
the first five years of the program and remained at 70% thereafter.21,22 Because the current
vaccine coverage rate is closer to 50% in the U.S., the reviewed published results might exhibit
12

some bias with that assumption. Implementing HPV vaccine promotion intervention is a main
approach to increase HPV vaccination rates. Future study should also consider the element of
the cost for any HPV vaccine promotion intervention designed to increase the HPV vaccine
coverage into the evaluation study.

13

Public Health Significance
In the U.S., the national and state-wide rates of HPV vaccine coverage are relatively low.
Interventions aimed at increasing HPV vaccine coverage are the main way to address this
concern. Because there are many factors involved in designing interventions, it is important to
understand what types of intervention are the most cost-effective. Furthermore, the costs for
developing and implementing these interventions should be included when conducting an
economic evaluation of the HPV vaccine program. In this study, a systematic review was
conducted to identify the evidence of HPV vaccine promotion interventions in the U.S.
Secondly, a cost-effectiveness analysis was conducted to identify what types of intervention
are the most cost-effective. The third aim is to incorporate the element of HPV vaccine
promotion intervention in the economic evaluation of HPV vaccine programs. This
information can provide evidence for policymakers when developing plans and policies related
to the administration of HPV vaccines.
Hypothesis, Research Question, Specific Aims or Objectives
The overall objective of this study is to conduct an economic evaluation of the
implementation of HPV vaccine promotion interventions. The study’s specific aims are:
1.

To identify evidence extracted from the existing literature that directly addresses
interventions aimed at increasing HPV vaccine coverage;

2.

To assess the cost-effectiveness in terms of increasing HPV vaccine coverage of the most
effective HPV vaccine promotion intervention in the U.S.;

3.

To assess the cost-utility in terms of QALYs gained by implementing the most effective
HPV vaccine promotion intervention in the U.S.
14

METHODS
Study Design
We first conducted a systematic review to identify the evidence related to interventions
aimed to increase the HPV vaccine coverage. The most cost-effective intervention strategy,
relative to the standard intervention, was identified using CEA. A cost-utility analysis (CUA)
was then developed to assess the life-years gained and QALYs gained after implementing the
HPV vaccine promotion interventions, compared with the standard intervention.
Data Collection
To identify evidence related to HPV vaccine promotion interventions, we searched
MEDLINE and PubMed to identify studies of interventions published during the period 2007
to 2017. Studies were included if the stated outcome was measured quantitatively as HPV
vaccine coverage rates. Study methods, intervention types, and results were extracted from the
included studies. For the data needed for the CUA study, we derived them from published
literature.
Human Subjects, Animal Subjects, or Safety Considerations
The IRB submission requirement was waived as this study used only published
literature for its data collections.

15

JOURNAL ARTICLE - 1
Systematic reviews of evidence regarding interventions designed to increase HPV
vaccine coverage
American Journal of Preventive Medicine
Background
Nearly 44,000 cases of HPV-associated cancer were diagnosed in the U.S. each year
between 2012 and 2016, and research data indicates that approximately 73% of these cases
were preventable through HPV vaccination.1 The safety and effectiveness of the HPV vaccine
have been proven in clinical trials. The vaccine series is recommended by the CDC for all
adolescents starting at age 9 up through 26 years. 2 However, HPV vaccine coverage in the U.S.
is low. According to the most recent data, only 53.7% of girls aged 13-17 years were up to date
with the HPV vaccine series in 2018.3 This coverage rate is far below the CDC’s Healthy
People target of 80% coverage by 2020. Underuse of the vaccine means that adolescents miss
an important opportunity to protect themselves against HPV-associated cancers. To increase
the vaccine’s coverage rate, implementing HPV vaccine promotion intervention is
fundamental. However, the strategies for these interventions are often heterogeneous, which
makes it’s challenging to determine the impact of those interventions. Furthermore, the
resources, such as costs of implementations varied across interventions and evidence of it is
little. A review that quantifies the intervention impact and identifies resources to implement
HPV vaccine promotion interventions is needed. We found a 2016 systematic review that
summarized evidence including intervention outcomes and costs of 34 HPV vaccine promotion
interventions.4 They found that many most of the interventions can significantly increase the
16

HPV vaccine coverage rates with modest costs. In our review, we have updated their results
which incorporated more recent studies and included all intervention techniques recommended
by the Community Guide (an independent literature review panel made up of public health and
prevention experts) for promoting vaccine coverage. In this systematic review, we presented
and summarized the results of the cost and effectiveness of the HPV vaccine promotion
interventions.
Methods
We used the Community Guide categorizing system to categorize intervention approaches
which included in our review. The Community Guide has identified the following intervention
approaches are used to promote immunization rates, including home visits, school
requirements, patient-held paper immunization records, patient/provider education, monetary
sanction policies, patient reminder and recall systems, provider assessment and feedback,
provider reminders, vaccination requirements for school attendance, vaccination programs in
schools, reducing out-of-pocket costs, standing orders, immunization information systems, and
multiple components interventions (combined two or more intervention strategies). 5
MEDLINE and PubMed were used to identify the published intervention methods intended to
increase HPV vaccine coverage during the period from 2007 to 2017. Three key Medical
Subject Heading (MeSH) terms were used for the search: ‘human papillomavirus’, ‘vaccine’,
and ‘intervention’. Details for searching keywords are listed in Table 1 of the Appendix. All
the relevant search literature was imported to RefWork (ProQuest) for citation management,
data selection, and duplicate checks. All the studies were screened by title and abstract to
ensure they qualified for inclusion. The eligibility criteria for inclusion and exclusion criteria
17

are listed in Table 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) was used as a guideline for conducting the review study. Extracted data included
these elements: author, year of publication, intervention participant characteristics including
age and gender, study sample size, intervention design, intervention setting, outcome
measurements and results, and intervention costs.
Meta-analysis was used to estimate the summarized effectiveness of each intervention
strategy. We assessed the outcome of the HPV vaccine completion rate which was measured
as the difference of the 3-dose HPV vaccine rate between the intervention and control groups.
A forest plot of effectiveness for the HPV vaccine promotion intervention was constructed.
Heterogeneity was assessed using I-squared (I2); an I2 ≤ 25% is considered minimal, 26% to
74% is moderate and ≥ 75% is excessive heterogeneity. All analyses were performed using
STATA (Stata, Release version 15).
Results
The literature selection process is presented in Figure 5. From among the initially
identified 1,782 unique articles, 56 were included in the review. The characteristics of the
studies included in the review are presented in Table 2. Intervention approaches used to
improve HPV vaccine coverage included patient reminder and recall systems, patient
education, provider assessment and feedback, provider reminders, reducing out-of-pocket
costs, school-based vaccine programs, vaccination requirements for school attendance,
standing orders, immunization information systems and multiple component interventions
(interventions implemented in combination involved more than two interventions). The age of
the study population ranged from 9 to 29 years old. In the review, 55.4% (N=31) of the
18

interventions focused exclusively on females.6,7,16–25,8,26–35,9,36,10–15 There were 11 studies
focused on specific populations, including low-income,11,37 Korean-American,9 AfricanAmerican,13 Haitian-American and African-American,18 Hispanic and African-American,38
Appalachian,19,22,24 women who served in the military,20 and Mexican-American.39
Effectiveness of interventions: Background and results
Patient reminder and recall system
Background: Under the patient reminder and recall system approach, members of the
target population are reminded if an HPV vaccination is due or late. Reminders and recalls are
delivered through various methods, including text messaging, prerecorded voice messages,
postcards, E-mail, telephone calls or standard mailed letters. 40
Evidence on effectiveness: We found 12 interventions (21.4%) used a patient reminder
and recall system to increase HPV vaccine coverage.7,8,45,46,9–11,37,41–44 Reminder and recall are
delivered by various methods, including text, voice message, postcard, mailing letter,
telephone call from the patient navigator, E-Mail and social media message. Interventions were
provided by health care providers, such as primary care providers or pediatricians. For the
study design, three were pre- and post-intervention studies

9,11,46

and nine were intervention

and control interventions.7,8,10,37,41–45 Among nine intervention and control studies, seven
included randomization7,10,37,41–44 and two are not randomization interventions.8,45 For the
outcome measure of the intervention, two measured HPV vaccine series initiation, 42,45 six
measured series completion,7,10,37,41,43,44 and one study measured both initiation and completion
rates.11 Two studies measured the percentage of receiving an HPV vaccine dose 9,46 and one
study measured the percentage of receiving the next HPV vaccine.8 Among studies comparing
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HPV vaccine series completion rate between intervention and control groups, the rate ranged
from -1.7% to 25% (median increase of 7.3%). One study found that the HPV vaccine series
completion rates of the mailed reminder, telephone reminder and standard care were 18%, 19%
and 14%, respectively.37 Another study compared the series completion rates involving the use
of telephone reminders versus text messages versus standard care; data indicated the telephone
reminder intervention resulted in an 8% increase over that of standard care, while the use of
text reminders resulted in an 18% increase compared to standard care. 43 Another study showed
intervention methods resulted in a 25% increase compared with usual care. 44 In one 2014 study,
they found that the HPV vaccine series completion rate was lower by 1.7% in the intervention
group as compared to that of the control group. 10
Evidence on economic: Three studies were included in the economic review (Table
3)37,42,46. One study estimated the cost of sending automated text, prerecorded voice, and
postcards to parents. Costs reported in the study were <$0.10 and $1.50 per automated message
and per postcard sent, respectively46. Another study estimated total operating costs, including
personnel and supply cost, of reminder and recall for immunizing adolescents in four private
pediatric practices. The total operating costs among the four practices ranged from $1,087 to
$1,34942. In Szilagyi et al. study, they conducted a randomized controlled trial of a managed
care-based patient reminder and recall system. They estimated the intervention costs were
$18.78 and $16.68 per adolescent per for mailed letter and telephone reminders, respectively 37.
Patient education
Background: The patient education approach provides accessible information to the
target populations and intends to change their attitudes about HPV vaccination. It is delivered
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via various methods such as online education intervention, written information (e.g. brochure,
posters, and news releases), educational videos, and educational curriculum content. 47,48
Evidence on effectiveness: Patient education is the most common approach used to
increase HPV vaccine coverage. Our search identified sixteen studies used patient education
to increase HPV vaccine coverage (28.6%)6,12,38,49–53,13–20 Six were pre- and post-intervention
studies,

16,20,49–52

while others were intervention and control studies. 6,12–14,17–19,38,50,53 A

majority of studies were conducted in health clinical settings (N=10). Effectiveness
measurements were heterogeneous across literature, including HPV vaccine initiation rate
(N=5),14,20,49,50,53 HPV vaccine completion rate (N=4),13,18,19,38 number/percentage of
participants receiving an HPV vaccine dose (N=4 ), 15,16,51,52 number/percentage of participants
receiving a needed HPV vaccine among who already initiated the first dose (N=2) 6,17 and the
cumulative HPV vaccination rate (N=1).12
Results for the HPV vaccine series completion rate varied widely across the studies.
Among studies comparing HPV vaccine series completion rate between intervention and
control groups, the rate ranged from -5.6% to 11.4% (median increase of 3%). In Sanderson et
al. (2017) study, the intervention consisted of two elements: provider/staff training sessions
and provision of patient educational materials included a video and a flyer promoting HPV
vaccine. After the intervention, the HPV vaccine completion rate was lower in the intervention
group versus the control group (12.4% versus 18.0%).38 Another study applied a clientcentered behavioral health education curriculum to the intervention technique, and results
show the HPV vaccine completion rate was slightly higher but not significantly in the
intervention group than the control group (10% versus 7%).18 Vanderpool et al. examined the
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effectiveness of an educational DVD intervention to promote HPV vaccine. After the
intervention, they found that 43.3% of the women randomized to the intervention group
completed 3 dose HPV series, whereas 31.9% of women in the control group completed the
series. 19
Evidence on economic: One study was identified which provided evidence on cost
(table 3)54. An education session was implemented using the print-based photonovella
intervention and iPad-based tailored interactive multimedia tool (TIMI) among Hispanic
parents. The study estimated costs by using print-based photonovella intervention and TIMI
were $88 and $108 per participant, respectively.
Vaccination requirements for school attendance
Background: HPV vaccination requirements are a response to legal rules or policies
that require adolescents attending a school to be vaccinated with HPV immunization as a
condition for school entry. Vaccination requirements vary across states according to
comprehensiveness, acceptable documentation of immunity, access to exemptions, and the
type and consistency of enforcement.55
Evidence on effectiveness: Three studies examined the effect of school entry
requirements and HPV vaccine coverage.28–30 Moss et al. compared the HPV vaccine series
initiation rate between states that had and had not adopted school entry vaccination
requirements; they found that states with the HPV vaccination requirement had a <1% increase
in the series initiation rate compared to that for states without the HPV vaccine requirement
(47.7% vs 47.3%).28 Another study found that states with either school-entry or education
mandates do not have higher HPV vaccine series completion rates compared to rates in states
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without such mandates.29 Potter et al. focused on the effect of Michigan’s school rule enacted
in 2010 that the HPV vaccine must be initiated for females. They found that the HPV vaccine
series initiation rate in females aged 13 enrolled in sixth grade after 2010 increased less than
5% over that for females enrolled before the requirement was implemented. 30 Results from the
three studies were consistent in demonstrating that HPV vaccine coverage was not significantly
different before and after the vaccination requirement.
Evidence on economic: No economic evidence of vaccination requirements for school
attendance was identified.
Provider assessment and feedback
Background: Provider assessment and feedback retrospectively assesses provider
performances about HPV vaccine delivery to a target population. Feedback may involve other
components such as benchmarks or incentives.56
Evidence on effectiveness: One study used provider assessment and feedback as a way
to improve HPV vaccine coverage. Perkins et al. found that the HPV vaccine series completion
rate increased to approximately 60% in both female and male case groups. 57 They concluded
that provider assessment and feedback have the potential to improve HPV vaccination rates,
yet more evidence is needed to fully assess the effects of the intervention.
Evidence on economic: No economic evidence of provider assessment and feedback
was identified.
Provider reminders
Background: Provider reminders inform those who administer the HPV vaccines know
that patients are due for a vaccination. Provider reminders are delivered in various ways,
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including notes or alerts posted in patients’ charts or electronic medical records, or letters sent
by mail or e-mail.58
Evidence on effectiveness: Two studies used provider reminders to promote the HPV
vaccine.21,59 They incorporated HPV vaccination reminders into electronic medical records or
reminder sheets for health care providers. Soon et al. found that the HPV series initiation rate
increased significantly between pre- and post-intervention (from 1.2% to 26.5%). 21 However,
Szilagyi et al. measured the HPV series completion rate and found that provider reminders
failed to improve the rate, concluding that more rigorous practice-based changes are needed to
promote the HPV vaccine.59
Evidence on economic: No economic evidence of provider reminder was identified.
Reducing client out-of-pocket costs
Background: Reducing client out-of-pocket costs involves programs that makes HPV
vaccination more affordable. Implementations can include making substitute payments for
vaccinations, providing insurance coverage, and lowering or eliminating patient out-of-pocket
expenses.60
Evidence on effectiveness: Three studies used reducing out-of-pocket costs to promote
the HPV vaccine.22–24 A voucher was provided to participants to redeem three doses of the
HPV vaccine at no cost. Two of the studies measured the HPV vaccine series initiation rate
before and after the intervention among Appalachian females 22,24 The series initiation rate
increased following intervention from 25% to 45%. The other intervention was implemented
at a university health clinic, and the change in the HPV vaccine series completion rate was
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measured before and after the intervention. Findings show that about 30% of the participants
received all three doses of HPV vaccine following the intervention. 23
Evidence on economic: No economic evidence of interventions designed to reduce
client out-of-pocket costs was identified.
Vaccination program in schools
Background: Vaccination programs in schools are an intervention under which the
HPV vaccine is delivered on-site to improve the immunization rate among the target
population. The intervention involves multiple components: immunization education and
promotion, assessment and tracking of vaccine status, referral of under-immunized students to
vaccination providers, and the actual provision of the vaccines. 60
Evidence on effectiveness: Four studies investigated the use of vaccination programs
in school as a means to increase HPV vaccine coverage. 25–27,61 Three were implemented at the
elementary and middle school level, and results showed increased series initiation rates ranging
from 5% to 35%.25,27,61 The fourth intervention was implemented at a university, and the HPV
vaccine series completion rate was measured. After the intervention, the completion rate rose
by almost 50% among the uninsured or underinsured students. 26
Evidence on economic: Two studies were included in the economic review

25,27

. One

study implemented a school-located adolescent vaccination program and estimated vaccine
administration costs were $23.98 per vaccine dose 25. Another study estimated total costs for
implementing school-located HPV vaccination clinics in partnership with a local health
department. The estimated total costs based on that study is 36% of the $376,104 budget, which
is equivalent to $135,398 27.
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Multiple components interventions
Background: Multiple components interventions involve two or more types of
intervention, such as the patient reminder and recall system plus patient education.
Evidence on effectiveness: Seven studies used the patient reminder and recall system
plus patient education as a mean to promote the HPV vaccine. 10,31,32,39,62–64 Five studies
measured the series completion rate31,39,62–64 and two reported on the series initiation rate10,32
for the HPV vaccine. Data addressing the results of the intervention effects were mixed. One
study found the HPV vaccine series completion rate was not significantly different between
measures of the intervention (34%) and the control (32%) groups. 62 Conversely, four studies
found significant differences for the HPV vaccine series completion rate between the
intervention and the control groups, with differences between them ranging from 13% to
55%.31,39,63
Two studies used the patient reminder and recall system plus the provider assessment
and feedback method as a means to promote HPV vaccine. 34,65 This intervention combined
reminder notifications for patients and feedback on immunization rates sent to providers. The
vaccine series completion rate increased by about 10% in both the intervention and control
groups.65
Two studies used patient education plus provider assessment and feedback as a means
to improve HPV vaccination rates.66,67 Results of this intervention’s effectiveness were
consistent in both studies. Findings indicate that the HPV vaccine series completion rate
increased by approximately 10% to 20% with the intervention.
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One study involved an intervention which combined three components: patient
reminder and recall system, provider reminder, and provider assessment and feedback. 35 The
researchers found that the HPV vaccine series completion rate was higher in the intervention
group than in the control group by 10%. Another intervention that included three components
(provider assessment and feedback, standing orders, and immunization information systems)
found the HPV vaccine series completion rate increased by about 1% after intervention. 36
Farmar et al. investigated an intervention method incorporating provider reminders, standing
orders, immunization information systems, and vaccination programs in school. Findings
showed the HPV series completion rate was higher in the intervention group in comparison
with national estimates.68 As observed, results for the effectiveness of multiple-component
intervention are mixed, and additional studies are needed for a better understanding.
Evidence on economic: One study was included in the economic review. 35 An
intervention that combined provider education, electronic health record-based alerts and audit
and feedback was implemented in primary care practices. Total costs for implementing the
combined intervention were $9,946 to administer the HPV vaccine dose 1 to 3 35.
Meta-analysis on summarized effectiveness of each intervention strategy
A meta-analysis was constructed to assess the outcome of the HPV vaccine completion
rate of interventions. We identified 21 studies that reported the difference of the HPV vaccine
completion rate between intervention and control studies. 5 studies were removed from the
analysis since the information on either the number of intervention participants or the number
of individuals completed the vaccine was not clear. 11,41,63,65,68 There were 24 intervention arms
in 16 studies included in the meta-analysis. Interventions of patient reminder and recall system,
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patient education, provider reminder, vaccination requirements for school attendance and
intervention combination were included in the meta-analysis. Other interventions were
excluded since the difference in HPV vaccine series completion rate between intervention and
control groups was not available.
A forest plot, stratified by the intervention strategy, is shown in Figure 6. Overall, the
percentage difference for increasing the HPV series completion between the intervention and
control groups was 8.0% (p-value < 0.05, indicating a significant difference in the outcome
between intervention and control groups). The highest summarized intervention effectiveness
is intervention combination (16%), followed by the patient reminder (10%) and patient
education (3%). For both the provider reminder and vaccination requirements for school
attendance, the difference in HPV vaccine completion rate between intervention and control
group was not statistically significant. We found that there was a great deal of heterogeneity
of interventions (I2 = 96%), indicating a high heterogeneity among studies.
Discussion
The purpose of this study was to identify and summarize published evidence on
interventions designed to increased HPV vaccine coverage in the U.S. We found 56 qualified
studies regarding interventions aimed to increase HPV vaccine coverage. We then extracted
data for the study population, intervention design, intervention results about changes related to
the HPV vaccine coverage, and intervention costs where available. Several systematic review
studies focusing on HPV vaccine promotion interventions were conducted, but the evidence is
not comprehensive. Fu et al. conducted a systematic review that identified HPV vaccine
promotion interventions, but they mainly focused on educational interventions. 69 In a 2015
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study, Niccolai et al. included only interventions conducted at the practice or community level,
including the patient reminder and recall system, physician-focused interventions, schoolbased programs, and multiple component interventions. 70 Other outcomes which are important
when evaluating an intervention (such as costs) are not synthesized across studies. We
identified interventions falling within the Community Guide’s categories for in increasing
vaccine coverage and documented both effectiveness and costs of interventions.
In the 56 qualified studies, patient education was identified as the most common
approach used to promote the HPV vaccine (N=16). However, the conclusions for the
intervention effectiveness were not consistent across the literature. In the Community Guide
report which focused on interventions of other immunizations, they found that there is
insufficient evidence to prove patient education is effective for promoting immunization. In
Fu. et al. systematic review of HPV vaccine promotion intervention, they also concluded that
there is no strong evidence to recommend patient education for implementation.

69

In our

review, the outcome measurement in patient education intervention studies was diverse. It was
difficult to directly compare outcome measures across studies. This suggests that there is a
need for more intervention research.
We identified 12 interventions that use the patient reminder and recall system to
promote the HPV vaccine. Using this approach to increase the vaccination rate is
recommended by the Community Guide. Regardless of the type of reminder and recall used
(e.g., text, email telephone), many studies indicated that the method generated a significant
increase for the HPV vaccine initiation and completion rates. 7,37,42–45 Overall, we found an
average increase of 10% in the HPV series completion rate after the intervention.
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Four interventions for applying the vaccine program in a school setting were identified
in the study. This intervention method is recommended by the Community Guide based on
strong evidence of its effectiveness at increasing vaccine coverage. Three of the four studies
measured the series initiation rate and found a significant increase in it following the
intervention.25,27,61 To better understand this intervention method’s impact on HPV vaccine
coverage, a study that measures the HPV vaccine series completion rate is needed in the future.
We found three articles which evaluated vaccination as a requirement for school
attendance. This intervention practice is also recommended by the Community Guide for
increasing vaccine coverage. However, none of the three studies included in our review found
a significant increase in HPV vaccine coverage after implementing this intervention. We note
that HPV vaccine awareness might differ from that of other adolescent vaccinations such as
Tdap and MCV4. More research addressing the differences in vaccine acceptance is needed.
We identified seven studies that cost data are available. Making a conclusion for the
intervention cost from included studies was challenging. Foremost, we found the information
about cost needed for intervention implementation was limited across the literature. In
addition, the methods of presenting intervention costs were heterogeneous across the
included programs, such as cost per mailing sent46 or cost per vaccine administered.25 cost
items reported in studies were diverse across the literature. For example, Karanth et al.
reported detailed information on cost items including personnel, material and participant
time.54 In a study by Bar-shain et al., cost information given in the study was only the cost
per message or mail sent.46 We recognize that cost estimates might be biased if the
information reported in the study was not comprehensive. We find that the cost of
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implementing an intervention is an important element when designing the intervention, and
further studies are needed to generate a better understanding.
One major limitation of this review was that many studies had limited generalizability in their
results. Of the studies identified in this review, there was a high amount of variability between
study populations and the intervention design. We found 11 studies focused on specific
populations, such as low-income or African-American females. Readers should be cautious
when generalizing results to the general population from rather selected groups. Some studies
had small sample sizes or were pre-post study design, it is difficult to state conclusively for the
intervention effectiveness. This review demonstrates the need for more studies with
population-level samples and randomized designs to better quantify intervention impacts.
Conclusions
We included 56 HPV vaccine promotion studies in the review. Intervention approaches
used to promote the HPV vaccine include patient reminder and recall systems (N=12), patient
education (N=16), provider assessment and feedback (N=1), provider reminder (N=2),
reducing out-of-pocket costs (N=3), school-based vaccine programs (N=4), vaccination
requirements for school attendance (N=3), and intervention combinations (N=14). We also
identified 7 studies that reported intervention costs. Most interventions significantly increased
HPV vaccine rates using varied approaches across populations and settings, and with modest
cost. The cost-effectiveness analysis is needed to determine which intervention type is the most
cost-effective.

31

Table 1. Inclusion and exclusion criteria for the systematic review
Inclusion
 Study design: Study has at least one comparison group to measure the
differences or changes of the HPV vaccine coverage.
 Intervention: Interventions designed to increase HPV vaccine coverage
 Outcome: Post-intervention HPV vaccination coverage. The differences or
changes must be reported and measured quantitatively.
Exclusion
 Post-intervention HPV vaccination rate was not available or not reported
quantitatively
 No original data
 Abstract or primary research only
 Study is not available in English
Figure 5. Flowchart for selecting the literature
2314 records identified from all sources
546 duplicates excluded
1768 titles & abstracts to screen
1532
-175
-941
-237
-96
-83
-00

Titles & abstracts excluded
Not conducted in the U.S.
Not an intervention study
Not focused on HPV vaccination
Not focused on cervical cancer
Included boys only
Did not have at least one comparison measurement
Outcome not available or not measured
quantitatively

181
-2
-71
-1
-00
-3
-103

Full text articles excluded
Not conducted in the U.S.
Not an intervention study
Not focused on HPV vaccination
Not focused on cervical cancer
Included boys only
Did not have at least one comparison measurement
Outcome not available or not measured
quantitatively

236 full text records to review

56 publications included
Reporting on 56 studies
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Table 2. The characteristics of studies included for the review
Author / year
Target population
Intervention (design, setting, intervention
(age, gender, sample and control conditions)
size)
Patient reminder and recall system (N=12)
Bar-Shain et al. 11-18 years old
-Pre- and post-intervention: Immunization
46
2015
female and male, N= message reminder including automated text,
Parents/guardians of prerecorded voice, and/or postcard
3,393 patients
-S: A large academic, tertiary, public health
system
Berenson et al.
2016 11

16-26 years old lowincome postpartum
female, N=1,038

-Pre- and post-intervention: Patient
navigator and reminder program including
text, mailing reminders and telephone call
-S: Public hospitals

Chao et al. 2015

9-26 years old
female, N (I)=9,760;
N(C)=2,445

-I: Reminder message and phone call for
HPV vaccine schedule and follow-up visits
to complete the vaccine
-C: Standard care
-S: The managed care organization Kaiser
Permanente Southern California

7
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Outcome (measurement, results)

-Among patients who needed a
vaccine, 22.9% received an HPV
vaccine

-Series initiation rate: increased from
25.4% before the intervention to
80.8% after the intervention.
-Series completion rate: increased
from 115.5% before the intervention
to 65.1% after the intervention
-Series completion rates for all
females aged 9-26 years old were
56.4% and 46.6% in I and C groups,
respectively
-Series completion rates for females
aged 9-17 years old were 66.2% and
53.5% in I and C groups,
respectively
-Series completion rates by females
aged 18-26 years old were 43.5% and
37.0% in I and C groups,
respectively

Chung et al.
2015 45

11-18 years old
female and male,
N(I)=1 county;
N(C)=4 counties

- I: Postcard reminder and school-generated
telephone reminders
-C: No intervention
-S: Medical practice settings including
family medicine practices, pediatric
practices, and the county health department

-Series initiation rate for females
aged 11-12 years old: improved by
27.4% to 43.4% in the intervention
group
-Series initiation rate for males aged
11-12 years old: improved by 14.2%
to 32.1% in the intervention group

Kempe et al.
201644

11-17 years old
female and male,
N(I)= 374;
N(C)=555

-I: Preference-based recall including text,
E-mail, auto-dialer and combined methods
-C: Usual care
-S: Kaiser Permanente Colorado Pediatrics
practices

-The rate for receiving 2 doses from
HER were 83% and 71% in I and C
groups, respectively
-Series completion rates from HER
were 63% and 38% in I and C
groups, respectively

Kharbanda et al.
2011 8

9-20 years old
female, N(I)=124;
N(C)=308

-I: Up to three weekly text message
reminders
-C: No text message reminder
-S: Pediatrics clinics in New York City

-I: 51.6% of females received their
next HPV vaccine dose
-C: 35.0% of females received their
next HPV vaccine dose

Lee et al. 2016 9

21-29 years old
Korean-American
female, N=30
19-26 years old
female, N(I)=180;
N(C)=185

-Pre- and post-intervention: 7-day text
message HPV intervention

- 30% of participants received their
first HPV vaccine dose

-I: Automated reminder message including
text, E-mail, phone, private Facebook
message, or standard mail
-C: Usual follow-up
-S: Outpatient reproductive health centers

-The rate for receiving 2 doses were
40.6% and 40% in I and C groups,
respectively
-Series completion rates within 32
weeks were 17.2% and 18.9% in I
and C groups, respectively

Patel et al. 2014
10
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Rand et al. 2015

11-16 years old
female and male,
N(I)=1,893;
N(C)=1,919

- I: Text message reminder and recall
system for HPV vaccination
-C: General adolescent health text messages
-S: Primary care practices

-Series initiation rates were 16% and
13% in I and C groups, respectively
-The rate for receiving 2 doses were
7% and 6% in I and C groups,
respectively
-Series completion rates were 2%
and 2% in I and C groups,
respectively

Rand et al. 2017

11-17 years old
female and male,
N(I1)=178;
N(C1)=180
N(I2)=191;
N(C2)=200

-I1: Telephone reminder
-C1: Standard care
-I2: Text message reminder
-C2: Standard care
-S: Urban primary care clinics

-For phone reminder, series
completion rates were 48% (85/178)
and 40% (72/180) in I1 and C1
groups, respectively
- For text reminder, series
completion rates were 49% (93/191)
and 31% (61/200) in I2 and C2
groups, respectively

Suh et al. 2012

11-18 years old
female and male,
N(I)=799; N(C)=797

-I: Reminder/recall for immunizing
adolescents with 2 letters and 2 calls
-C: Usual care
-S: Private pediatric practices in
metropolitan Denver

-Series initiation rate from Colorado
Immunization Information System:
-I: 26.5%
-C: 15.3%

-I1: Mailed letter
-I2: Telephone reminder
-C: Standard care
-Primary care practices

-Series completion rates from
insurance claims files:
-I1: 18%
-I2: 19%
-C: 14%

41
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Szilagyi et al.
2013 37

11-17 years old lowincome female and
male, N(I1)=1,396;
N(I2)=1,423;
N(C)=1,296
Patient education (N=16)
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Bennett et al.
2015 6

18-26 years old
female,
N(I)=330; N(C)=331

-I: An individually tailored, online
-42.9% of participants who received
educational intervention on HPV vaccinethe first dose HPV vaccine received a
related knowledge, vaccination intention,
second dose in each group.
and uptake among students
-C: Online education from the CDC vaccine
information statement
-S: A Midwestern university

Cates et al. 2011

9-13 years old
female,
N(I)=4 NC counties
including Richmond,
Harnett, Robeson
and Cumberland;
N(C)=9 NC counties

-I: Provided HPV vaccine promotion
information through posters, brochure,
websites, news releases and doctor’s
recommendations among parents
-C: no intervention
-S: Health care provider’s offices and
community including pharmacies, salons
and grocery stores

-Cumulative HPV vaccination rates
by age 9-13 from immunization
registry system:
-I (Richmond): 7.1%
-I (Harnett): 6.8%
-I (Robeson): 3.2%
-I (Cumberland): 1.9%
-C: 5%

DiClemente et
al. 2015 13

14-18 years old
African-American
female,
N(I)=108;
N(C)=108

-I: Innovative culturally tailored, computerdelivered media-based intervention (Girls
OnGuard) to improve HPV knowledge,
vaccine motivation and behavioral skills
among adolescents
-C: No intervention
-S: Family planning and sexual transmitted
infection public health clinics in
metropolitan Atlanta

-6% (6/108) received doses 2 and 3
in the intervention group; 2% (2/108)
received doses 2 and 3 in the control
group; data from medical records

Gerend et al.
201214

18-26 years old
female, N (I1)=250;
N (I2)=243;

-I1: Educational video with gain-framed
information for HPV vaccination and HPV
infection
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-Series initiation rates by self-report:
-I1: 5%
-I2: 6%

12

N (C)=246

-I2: Educational video with loss-framed
information for HPV vaccination and HPV
infection
-C: Educational video with no framed
information for HPV vaccination and HPV
infection
-S: A large southeastern university in the
U.S.

-C: 7%

Groom et al.
2017 49

11-18 years old
female and male

-Pre- and post-intervention: Education
session combining information on HPV
infection, parental communication
strategies, and facility-specific coverage
data among adolescents among health care
team members such as administrative,
medical assistants, nurses, medical doctors
-S: Primary care facilities within the Kaiser
Permanente Northwest health care system

-Series initiation rate for female:
increased by 1%
-Series initiation rate for male:
increased by 3%

Hohmeier et al.
201650

9-26 years old
female and male,
21 questionnaire
respondents

-Pre- and post-intervention: A pharmacistled, multimodal educational intervention
approach
-S: A community pharmacy setting

-Series initiation rate: increased to
48%

Hopfer 201215

18-26 years old
female,
N=404

-I1: A narrative video with peer narrative
intervention
-I2: A narrative video with medical expert
narrative intervention
-I3: A narrative video with combined peer
and medical expert narrative intervention
37

-Series initiation rates by self-report:
-I1: 18%
-I2: 6%
-I3: 22%
-C: 12%

-C: No intervention
-S: A university health center
JiménezQuiñones et al.
2017 51

18-26 years old
female and male,
N=79

-Pre- and post-intervention: pharmacist
conducted educational program that
educational materials and counseling
regarding HPV vaccination were provided
to patients
-S: A pharmacy in Farmacia San José,
Lares, PR

-4 patients received an HPV vaccine
dose after the intervention

Obulaney et al.
2016 16

9-18 years old
female,
N=41

-Pre- and post-intervention: Nurse
practitioner-led language-appropriate
cervical cancer prevention educational
session among mothers and daughters
-S: A low-cost, faith-based clinic

-HPV vaccine rate increased from
5.4% to 18% after the intervention

Parra-Medina et
al. 2015 17

11-17 years old
Hispanic female,
N(I)=257, N(C)=115

-I: Entre Madre e Hija (EMH): A culturally
relevant cervical cancer prevention program
and HPV vaccine educational brochure
-C: HPV vaccine educational brochure
-S: Community resource centers

Pierre Joseph et
al. 2016 18

11-15 years old
Haitian American
and African
American female
N(I)=100; N(C)=100

-I: A client-centered behavioral health
education curriculum among mothers
-C: Low-literacy, standard-practice HPV
vaccine information sheet
-S: Primary care practices of a large urban
hospital

-84% of participants in both I and C
groups initiated HPV vaccination.
Series completion rates among those
who received HPV vaccine dose 1:
-I: 72.2%
-C: 42.5%
-Series completion rates from EHR:
-I: 10%
-C: 7%
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Rickert et al.
2015 52

11-15 years old
female and male,
N=445

-Pre- and post-intervention: A parent health
education with rhetorical or non- rhetorical
question and one-sided or two-sided
message among parents
-S: Teen Health Center

-151 participants received their first
dose (34%)

Sanderson et al.
2017 38

9-18 years old
African American
and Hispanic female
and male, N(I)=150
families (194
children); N(C)=119
families (167
children)

-I: Provider/staff training sessions and
provision of patient education materials
-C: no intervention
-S: 4 Safety-net pediatric clinics

-Series completion rates from
medical records:
-I: 12.4%
-C: 18.0%

Staras et al.
201453

11-17 years old
female and male,
N(I1)=2,839;
N(C1)=2,824;
N(I2)=1,774;
N(C2)=3,889;
N(I3)=886;
N(C3)=1,936

-I1: Postcard campaign: address the gender
diversity in vaccine series initiation and
differential parent concerns. It was used to
urge parents to discuss vaccination with the
health care’s providers.
-I2: In-clinic health information technology
(HIT) system: to verify adolescent’s
vaccination history and indicate interest in
learning the vaccine. It reminded providers
if the adolescents agreed to the vaccination.
-I3: Postcard campaign and in-clinic HIT
system
C1-C3: Usual care
-S: Primary care clinics in North Central
Florida
39

-Series initiation rates among girls:
-I1=5.5%; C1=3.6%
-I2=6.0%; C2=4.8%
-I3=7.5%; C3=3.1%
-Series initiation rates among boys:
-I1=5.7%; C1=5.4%
-I2=7.0%; C2=4.8%
-I3=7.2%; C3=4.7%

Vanderpool et
al. 2013 19

Mean age of 22 years -I: Educational DVD for HPV vaccination
old Appalachian
-C: Standard care
female, N(I)=178;
-S: Community
N(C)=166

-Series completion rate:
-I=43.3%
-C=31.9%

Wedel et al.
2016 20

18-26 years old
military female,
N=103

-Series initiation rate: increased from
55% to 91%

-Pre- and post-intervention: patient
education and provider recommendation
program
-S: A medical facility in southern California
Provider assessment and feedback (N=1)
Perkins et al.
11-12 years old
-I: Provider-focused intervention that
2015 57
female and male,
included individualized feedback that
N(I)=4093;
showed providers’ performance compared
N(C)=9025
to others in immunization rates, and quality
improvement incentives when
demonstrating improvements in
immunization rates
-C: No intervention
-S: Federally qualified community health
centers
Provider reminders (N=2)
Soon et al. 2017 18-26 years old
-Pre- and post-intervention: the electronic
21
female, N=241
medical record prompt on HPV vaccine
-S: An outpatient clinic
Szilagyi et al.
11-17 years old
-I: In the first strategy, an electronic health
2015 59
female and male,
record appeared on the providers’ computer
N(I)= 11 clinics (5
screen to indicate the specific
GR-PBRN practices immunizations that adolescents were
recommended to receive (EHR-Prompt). In
40

-Completion of next needed dose of
HPV vaccine among females:
increased from 44% to 56% in the
intervention group and from 40% to
44% in the control group
- Completion of next needed dose of
HPV vaccine among males:
increased from 1% to 59% in the
intervention group and from 13% to
41% in the control group
-HPV vaccine uptake: increased from
1.2% to 26.5% after the intervention
-Series completion rates among
females in GR-PBRN clinics
remained unchanged at 51%in the
intervention group, but increased

and 6 CORNET
practices),
N(C)= 11 clinics (5
GR-PBRN practices
and 6 CORNET
practices)

Reducing out-of-pocket costs (N=3)
Casey et al.
18-26 years old
22
2013
Appalachian female,
N=495

the second, a nurse- or staff-initiated
provider prompt appeared on the providers’
reminder sheet (Staff-Prompt)
-C: Standard-of-care without prompts
-S: Pediatric or family medicine clinics in
the Practice-based research networks
(PBRN)

from 51% to 53% in the control
groupa
-Series completion rates among
females in CORNET clinics
increased from 48% to 50% in the
intervention group, but decreased
from 44% to 42% in the control
groupb

- Pre- and post-intervention: Free voucher
to receive three doses of HPV vaccine
series
-S: (1) Health clinics for primary care and
women’s health service; (2) Community
college

-Series initiation rate: increased to
25.9%

Moore et al.
2010 23

18-24 years old
female,
N=209

-Pre- and post-intervention: Free voucher to
receive three doses of HPV vaccine series
-S: A university health clinic

-Series completion rate: increased to
28.2%

Vanderpool et
al. 2011 24

18-26 years old
Appalachian female,
N=247

-Pre- and post-intervention: Free voucher to
receive three doses of HPV vaccine series
-S: Health clinics in rural counties of
Southeastern, Kentucky

-Series initiation rate: increased to
44.9%

-I: Three-day school-located adolescent
vaccination program. The vaccine program
is in partnership with a local health
department
41

-Percentages of receiving one or
more doses among students needing
vaccine (6th grade): 34% in the

Vaccination program in school (N=4)
Daley et al.
6th to 8th grade
2014 25
female
N(I)=7 schools
(median number of

students =289);
N(C)=7 schools
(median number of
students=350)

-C: No intervention
-S: Vaccination clinics at seven Denver
public schools

Eldred et al.
2015 61

Middle school
female and male,
N=184

-Pre- and post-intervention: Medical
student-driven “vaccine blitzes” to
vaccinate all consenting students. Vaccines
were given by a team of medical students,
public health students and school-based
health center staff
- S: School-based health center

Navarrete et al.
2014 26

≥19 years old female, -Pre- and post-intervention: a pharmacistN=89
operated HPV vaccine program utilizing
patient assistance program (PAP). The
pharmacist administered the HPV vaccine
for the uninsured and underinsured student
population.
-S: University of Texas at El Paso
University Student Health Clinic Pharmacy

Stubbs et al.
2014 27

Middle school
female, N(I)=6
schools; N(C)=15
schools

intervention group and 18% in the
control group
- Percentages of receiving one or
more doses among students needing
vaccine (7th and 8th grade): 20% in
the intervention group and 7% in the
control group
-Series initiation rate among girls:
increased from 7% to 41%
-Series initiation rate among boys:
increased from 7% to 31%

-Series completion rate:
increased to 48.3%

-I: Hosted a 4-day school-located HPV
-Series initiation rates: 6% in the
vaccination clinic which provided free HPV intervention group and 1% in the
vaccine to the study. The vaccine program
control group
is in partnership with a local health
department.
42

-C: Students could receive the HPV vaccine
at the intervention school clinics
-S: Middle schools in Guilford county, NC
Vaccination requirements for school attendance (N=3)
Moss et al. 2016 13-17 years old
-I: State school entry requirements for
28
female, N=47,742
adolescent vaccination (Virginia and the
District of Columbia)
-C: No state school entry requirements for
adolescent vaccination
Perkins et al.
2016 29

13-17 years old
female, N(I1)=1,649;
N(I2)=12,579;
N(C)=33,617

-I1: School-entry mandates for HPV
vaccination (Virginia and the District of
Columbia)
-I2: Mandates of education to parents or
provision of education within school
curricula (LA, MI, CO, IN, IA, IL, NJ, NC,
TX, WA)
-C: No mandates

Potter et al,
2014 30

6th grade female,
N=264,789

-Pre and post-intervention: initiation of the
HPV vaccine series required for 6th grade

-Series initiation rates by the analysis
of 2008-2012 National Immunization
Survey-Teen: 47.7% in the
intervention group and 47.3% in the
control group
-Series completion rates by the
analysis of the 2009 – 2013 National
Immunization Survey-Teen
-I1: increased from 28% to 39%
-I2: increased from 29% to 37%
-C: increased from 29% to 38%

-Series initiation rate (analysis of the
Michigan Care Improvement
Registry): increased less than 5%
after the intervention
Intervention combination: Patient reminder and recall system+ patient education (N=7)
Aragones et al.
9-17 years old
-I: Parental education and a text messaging -Series completion rates among those
2015 39
Mexican-American
reminder intervention
who received the first dose by selfmale and female,
-C: education onsite only
reported:
N(I)=45; N(C)=24
-S: A non-clinical, trusted community
-I: 88%
setting
-C: 40%
43

Cassidy et al.
2014 31

11-12 years old
female,
N(I)=24; N(C)=29

-I: Evidence-based educational brochure
and reminder system
- C: no intervention
- S: Private pediatric practice in an urban
location

-Series completion rates by selfreported:
-I: 62.5%
-C: 6.9%

Paskett et al.
2016 32

9-17 years old
Appalachian female:
N(I)=174, N(C)=163

-I: HPV education materials using
examination room poster, brochures and
tabletop + a magnet reminder for the 2nd
and 3rd HPV vaccine shot
-C: No intervention
-S: Clinics in Appalachia Ohio

Series initiation rates from medical
records:
-I: 13.1%
-C: 6.5%

Patel et al. 2012

18-26 years old
female: N= 256

-I: HPV education with a mailed reminder
-C: standard care
-S: A university health service gynecology
clinic

Series initiation rates from medical
records:
-I: 5.5%
-C: did not differ by intervention
group

Richman et al.
2016 62

18-26 years old
female and male,
N(I)=129; N(C)=133

-I: Text/ E-mail appointment reminders and
education message
-C: standard of care
-S: A University health center in North
Carolina

-Series completion rates from student
health records:
-I: 34%
-C: 32%

Tiro et al. 2015

11-18 years old
female and male,
N(I)=410; N(C)=404

-I: HPV vaccine-specific brochure and
reminder calls;
-C: General vaccine brochure
-S: 4 safety-net pediatric clinics
44

-Series completion rates from
electronic health records:
-I: 28.7%
-C: 15.6%

33

63

Vanderpool et
al. 2015 64

9th to 12th grade
female and male,
N=447

McLean et al.
2017 65

11-17 years old
female and male,
N(I)=16,401;
N(C)=8,617

-Pre and post-intervention: A school-based -Series completion rate:
HPV vaccine program. The vaccine
increased from 14% to 45%
program is in partnership with a local health
department. The intervention included HPV
educational materials and telephone
reminder calls
-S: School health centers in rural southcentral Kentucky
Intervention combination: Patient reminder and recall system+ provider assessment and feedback (N=2)
Mazzoni et al.
15-26 years old
-Pre- and post-intervention: Reminder/
Series initiation rate: increased from
34
2016
female,
recall program, give provider feedback on
7.1% to 23.7%
N=4869
immunization and staff education
-S: Obstetrics and gynecology clinics at a
public integrated health-care system
-I: Provider and staff education, quarterly
feedback to providers and patient reminder
and recall notices
-C: No intervention
-S: Pediatrics and family practices in
Marshfield Clinic Health System

-Series completion rates among 1112 adolescents:
-I: increased from 32.0% to 52.7%
-C: increased from 31.6% to 52.3%
-Series completion rates among 1317 adolescents:
-I: increased from 59.4% to 71.9%
-C: increased from 55.5% to 66.9%
Intervention combination: Patient education+ provider assessment and feedback (N=2)
Jacobs-Wingo et 13-17 years old
- Pre- and post-intervention: Analyzing and Series completion rate from facility’s
al. 2017 66
American Indian
providing feedback on facility vaccine
EHR: increased from 20% to 42%
female and male,
coverage data + patient and provider
N=6,239 (14
education
facilities)
45

- S: Indian Health Service, triballyoperated, and urban Indian (I/T/U)
healthcare facilities
Zimmerman et
al. 2017 67

11-13 years old
female and male,
N(I)=4942;
N(C)=5919

- I: Educated patients about the importance -Series completion rates from EHR
of immunization and the availability of
-I: from 31.3% to 44.1%
vaccines, and provided assessment and
-C: from 37.3% to 50.0%
feedback on immunization rates while
motivating physicians through an ofﬁce
immunization champion
-C: No intervention
-S: Primary care family medicine and
pediatric practices in Pittsburgh and
Southwestern Pennsylvania
Intervention combination: Provider education + provider reminder+ provider assessment and feedback (N=1)
Fiks et al. 2013
11-17 years old
-I1(Family-focused intervention):
Series completion rates:
35
female,
Automated educational reminder calls for
-I1: 73%
N (I1)=5,680;
patients
-I2: 67%
N (I2)=5,557;
-I2(Clinician-focused intervention): EHR-I3: 76%
N (I3)=5,561;
based clinician-focused vaccine alerts+
-C: 63%
N (C)=5,688
automated educational reminder calls for
patients+ performance feedback reports for
vaccine delivery
-I3(Combined intervention): I1 and I2
combined intervention
-C: Standard of practice
-S: The Children's hospital of Philadelphia
Pediatric
Intervention combination: Provider assessment and feedback + standing orders + immunization information systems
(N=1)
46

Moss et al. 2012

-Pre- and post-intervention: a webinar that
-Series completion rate from NC
reviewed provider-based changes and
immunization registry: increased
weekly follow-up E-mails, provided
from 21% to 22%
incentives and identified the champion on
immunization practices. Clinic staffs
learned to use standing orders and the North
Carolina Immunization Registry to improve
immunization rates
- S: Federally qualified health centers
Intervention combination: Provider reminders + standing orders + immunization information systems + vaccination
program in school (N=1)
Farmar et al.
13-17 years old
I: Clinic staffs checked vaccine registry for -Series completion rates among girls
2016 68
female and male,
recommended vaccines at every visit.
from vaccine registry: 66.0% in the
N=11463
Routine use of a vaccine registry and
intervention group versus 37.6%
standing order for the vaccination to be
nationally
administered to the patient. Vaccination
-Series completion rates among boys
drives at school health centers were offered. from vaccine registry: 52.5% in the
-C: compared with national HPV vaccine
intervention group versus 13.9%
coverage
nationally
-S: Denver Health: an integrated urban
safety net health system
SES: Social economic status; I: Intervention; C: Control; CDC: Centers for Disease Control and Prevention; NC: North Carolina;
EHR: Electronic health record; PR: Puerto Rico
36

12-17 years old
female,
N=17 clinics

47

Table 3. Study characteristics for the included economic studies
Author/year Intervention types
Evidence relevant to costs in the study
Patient reminder and recall systems
Bar-Shain et Immunization
-5,965 text and phone messages sent; <$.10 per
46
al. 2015
message reminder
automated message for e-mail, text, and phone
including automated messages
voice, texts and
-1,129 postcards sent; $1.50 per postcard
postcards
Suh et al.
Consisted of up to 2 -Total operating costs in four implemented
2012 42
letters separated by
practices=$1,119+$1,245+$1,349+$1,087=$4,800
2 autodialed
-Total personnel costs in four implemented
telephone calls
practices=$589+$420+$622+$458=$2,089
-Total supply costs in four implemented
practices=$530 +$825+$727+$629=$2,711
Szilagyi et
Included reminder
-The cost for the mailed reminder letter was
37
al. 2013
letters and telephone $18.78 per adolescent
- The cost for the telephone reminder was $16.68
per adolescent
-The cost for the mailed reminder letter was
$463.99 per additional adolescent fully vaccinated
-The cost for the telephone reminder was $714.95
per additional adolescent fully vaccinated
Patient education
Karanth et
i-Pad based tailored -TIMI: Total direct cost including personnel and
54
al.
interactive
material cost=$80.64 per participant; Overhead
multimedia
cost=$24.19 per participant; Participant time
intervention (TIMI) cost=$2.99 per participant
or print based
-Photonovella: Total direct cost including
(Photonovella)
personnel and material cost=$65.49 per
participant; Overhead cost=$19.65 per
participant; Participant time cost=$2.36 per
participant
Vaccination program in school
Daley et al.
School-located
-A total of 1,505 vaccines administered; the
2014 25
vaccination program estimated program administration costs were
$23.98 per vaccine administered
Stubbs et al. School-located HPV -Total costs were 36% of the $376,104 budget=
2014 27
vaccination clinics
$135,398
Provider education+ provider reminder+ provider assessment and feedback
Fiks et al.
EHR-based vaccine -Family-focused intervention: Total costs for
2013 35
alerts+ automated
administering HPV vaccine 1 to 3 were $2,455
educational
48

reminder calls for
patients+
performance
feedback reports for
vaccine delivery

-Clinician-focused intervention: Total costs for
administering HPV vaccine 1 to 3 were $7,488
-Combined intervention: Total costs for
administering HPV vaccine 1 to 3 were $9,946

49

Figure 6. Forest plot for the outcome effect of HPV vaccine promotion interventions on
HPV series completion rate
Treatment
Yes
No

Study

Control
Yes
No

Risk Diff.
with 95% CI

Weight
(%)

Intervention combination
Aragones, 2015

39

6

10

14

0.45 [ 0.23, 0.67]

1.92

Cassidy, 2014

15

9

2

27

0.56 [ 0.34, 0.77]

1.99

Richman, 2016

44

85

43

90

0.02 [ -0.10, 0.13]

3.52

2,179 2,763

2,960

2,959

-0.06 [ -0.08, -0.04]

5.01

Zimmerman, 2017
Fiks, 2013 (Family-focused intervention)

116

43

120

71

0.10 [ 0.00, 0.20]

3.84

Fiks, 2013 (Clinician-focused intervention)

90

44

120

71

0.04 [ -0.06, 0.15]

3.70

Fiks, 2013 (Combined intervention)

90

28

120

71

0.13 [ 0.03, 0.24]

3.74

2

2

2

Heterogeneity: t = 0.03, I = 94.26%, H = 17.43

0.16 [ 0.01, 0.30]

Test of ?i = ?j : Q(6) = 74.93, p = 0.00
Patient education
DiClemente, 2015

6

102

2

106

0.04 [ -0.01, 0.09]

4.67

Pierre Joseph, 2016

10

90

7

93

0.03 [ -0.05, 0.11]

4.22

Sanderson, 2017

24

170

30

137

-0.06 [ -0.13, 0.02]

4.27

Vanderpool, 2013

77

101

53

116

0.12 [ 0.02, 0.22]

3.77

2

2

2

Heterogeneity: t = 0.00, I = 48.94%, H = 1.96

0.03 [ -0.02, 0.08]

Test of ?i = ?j : Q(3) = 8.11, p = 0.04
Patient reminder
Chao, 2015 (9-17 yr)

3,680 1,883

759

659

0.13 [ 0.10, 0.16]

4.93

Chao, 2015 (18-26 yr)

1,824 2,373

380

647

0.06 [ 0.03, 0.10]

4.89

Chao, 2015 (9-26 yr)

5,504 4,256

1,139

1,306

0.10 [ 0.08, 0.12]

4.99

Kempe, 2016 (3 doses)

236

138

211

344

0.25 [ 0.19, 0.31]

4.47

Patel, 2014 (3 doses)

31

149

35

150

-0.02 [ -0.10, 0.06]

4.19

Rand, 2017 (Phone, 3 doese)

85

93

72

108

0.08 [ -0.02, 0.18]

3.74

Rand, 2017 (Text, 3 doese)

93

98

61

139

0.18 [ 0.09, 0.28]

3.88

Szilagyi, 2013 (Mailed letter)

78

355

58

356

0.04 [ -0.01, 0.09]

4.69

Szilagyi, 2013 (Phonel)

84

358

58

356

0.05 [ 0.00, 0.10]

4.68

2

2

2

Heterogeneity: t = 0.00, I = 89.75%, H = 9.76

0.10 [ 0.05, 0.14]

Test of ?i = ?j : Q(8) = 50.01, p = 0.00
Provider reminder
Szilagyi , 2015 (GR-PBRN)

201

196

221

200

-0.02 [ -0.09, 0.05]

4.38

Szilagyi , 2015 (CORNET)

237

241

200

276

0.08 [ 0.01, 0.14]

4.47

2

2

2

Heterogeneity: t = 0.00, I = 49.14%, H = 1.97

0.03 [ -0.03, 0.10]

Test of ?i = ?j : Q(1) = 3.94, p = 0.05
School requirement
Perkins, 2016 (School-entry mandates)
Perkins, 2016 (Education mandates)
2

2

643 1,006 12,774 20,843

0.01 [ -0.01, 0.03]

4.97

4,654 7,925 12,774 20,843

-0.01 [ -0.02, -0.00]

5.05

2

Heterogeneity: t = 0.00, I = 0.00%, H = 1.00

-0.01 [ -0.02, 0.00]

Test of ?i = ?j : Q(1) = 2.25, p = 0.13
Overall

0.07 [ 0.04, 0.11]
2

2

2

Heterogeneity: t = 0.01, I = 95.52%, H = 22.30
Test of ?i = ?j : Q(23) = 335.06, p = 0.00
Test of group differences: Q b(4) = 24.66, p = 0.00
0
Random-effects ML model

50

.5

1

References
1.

2.
3.

4.
5.
6.

7.

8.
9.
10.

11.
12.

13.

14.

Senkomago V, Henley S, Thomas C, Mix J, Markowitz L, Saraiya M. Human
Papillomavirus–Attributable Cancers — United States, 2012–2016. MMWR
Morb Mortal Wkly Rep. 2019;68:724-728.
doi:http://dx.doi.org/10.15585/mmwr.mm6833a3
Centers for Disease Control and Prevention. HPV Vaccine Schedule and
Dosing. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html.
Published 2019. Accessed January 11, 2019.
Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and
Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17
Years — United States, 2018. MMWR Morb Mortal Wkly Rep.
2019;68(33):718-723.
Smulian E, Mitchell K, Stokley S. Interventions to increase HPV vaccination
coverage: A systematic review. Hum Vaccin Immunother. 2016;5515(ePub
ahead of print). doi:10.1080/21645515.2015.1125055
Vaccination. The Community Guide.
https://www.thecommunityguide.org/topic/vaccination. Published 2020.
Accessed January 8, 2020.
Bennett AT, Patel DA, Carlos RC, et al. Human Papillomavirus Vaccine
Uptake After a Tailored, Online Educational Intervention for Female
University Students: A Randomized Controlled Trial. J Women’s Heal.
2015;24(11):950-957. doi:10.1089/jwh.2015.5251
Chao C, Ph D, Preciado M, Slezak J, Xu L. Original article A Randomized
Intervention of Reminder Letter for Human Papillomavirus Vaccine Series
Completion. J Adolesc Heal. 2015;56(1):85-90.
doi:10.1016/j.jadohealth.2014.08.014
Kharbanda EO, Stockwell MS, Fox HW, Andres R, Lara M, Rickert VI. Text
message reminders to promote human papillomavirus vaccination. Vaccine.
2011;29(14):2537-2541. doi:10.1016/j.vaccine.2011.01.065
Lee HY, Koopmeiners JS, McHugh J, Raveis VH, Ahluwalia JS. mHealth Pilot
Study: Text Messaging Intervention to Promote HPV Vaccination. Am J Health
Behav. 2016;40(1):67-76. doi:10.5993/AJHB.40.1.8
Patel A, Stern L, Unger Z, et al. Staying on track: A cluster randomized
controlled trial of automated reminders aimed at increasing human
papillomavirus vaccine completion. Vaccine. 2014;32(21):2428-2433.
doi:10.1016/j.vaccine.2014.02.095
Berenson AB, Rahman M, Hirth JM, Rupp RE, Sarpong KO. A human
papillomavirus vaccination program for low-income postpartum women. Am J
Obstet Gynecol. 2016;215(3):318.e1-318.e9. doi:10.1016/j.ajog.2016.02.032
Cates JR, Shafer A, Diehl SJ, Deal AM. Evaluating a County-Sponsored Social
Marketing Campaign to Increase Mothers’ Initiation of HPV Vaccine for their
Pre-teen Daughters in a Primarily Rural Area. Soc Mar Q. 2011;17(1):4-26.
doi:10.1080/15245004.2010.546943
DiClemente RJ, Murray CC, Graham T, Still J. Overcoming barriers to HPV
vaccination: A randomized clinical trial of a culturally-tailored, media
intervention among African American girls. Hum Vaccin Immunother.
2015;5515(January):1-12. doi:10.1080/21645515.2015.1070996
Gerend MA, Shepherd JE. Predicting human papillomavirus vaccine uptake in
young adult women: Comparing the Health Belief Model and Theory of
51

15.
16.

17.

18.

19.
20.
21.
22.

23.
24.
25.

26.

27.
28.

Planned Behavior. Ann Behav Med. 2012;44(2):171-180. doi:10.1007/s12160012-9366-5
Hopfer S. Effects of a Narrative HPV Vaccination Intervention Aimed at
Reaching College Women: A Randomized Controlled Trial. Prev Sci.
2012;13(2):173-182. doi:10.1007/s11121-011-0254-1
Obulaney PA, Gilliland I, Cassells H. Increasing Cervical Cancer and Human
Papillomavirus Prevention Knowledge and HPV Vaccine Uptake through
Mother/Daughter Education. J Community Health Nurs. 2016;33(1):54-67.
doi:10.1080/07370016.2016.1120595
Parra-Medina D, Morales-Campos DY, Mojica C, Ramirez AG. Promotora
outreach, education and navigation support for HPV vaccination to Hispanic
women with unvaccinated daughters. J Cancer Educ. 2015;30(2):353-359.
doi:10.1007/s13187-014-0680-4
Pierre Joseph N, Bernstein J, Pelton S, et al. Brief Client-Centered
Motivational and Behavioral Intervention to Promote HPV Vaccination in a
Hard-to-Reach Population: A Pilot Randomized Controlled Trial. Clin Pediatr
(Phila). 2016;55(9):851-859. doi:10.1177/0009922815616244
Vanderpool RC, Cohen E, Crosby RA, et al. “1-2-3 Pap” Intervention
Improves HPV Vaccine Series Completion among Appalachian Women. J
Commun. 2013;63(1):95-115. doi:10.1111/jcom.12001
Wedel S, Navarrete R, Burkard JF, Clark MJ. Improving Human
Papillomavirus Vaccinations in Military Women. Mil Med.
2016;181(10):1224-1227. doi:10.7205/MILMED-D-15-00477
Soon R, Sung S, Cruz MR Dela, Chen JJ, Hiraoka M. Improving human
papillomavirus (HPV) vaccination in the postpartum setting. J Community
Health. 2017;42(1):66-71. doi:10.1007/s10900-016-0230-6
Casey BR, Crosby RA, Vanderpool RC, Dignan M, Bates W. Predictors of
Initial Uptake of Human Papillomavirus Vaccine Uptake Among Rural
Appalachian Young Women. J Prim Prev. 2013;34(0):71-80.
doi:10.1007/s10935-013-0295-2
Moore GR, Crosby RA, Young A, Charnigo R. Low rates of free human
papillomavirus vaccine uptake among young women. Sex Health.
2010;7(3):287-290. https://doi.org/10.1071/SH09136.
Vanderpool RC, Casey BR, Crosby RA. HPV-related risk perceptions and
HPV vaccine uptake among a sample of young rural women. J Community
Health. 2011;36(6):903-909. doi:10.1007/s10900-010-9345-3
Daley MF, Kempe A, Pyrzanowski J, et al. School-located vaccination of
adolescents with insurance billing: Cost, reimbursement, and vaccination
outcomes. J Adolesc Heal. 2014;54(3):282-288.
doi:10.1016/j.jadohealth.2013.12.011
Navarrete JP, Padilla ME, Castro LP, Rivera JO. Development of a community
pharmacy human papillomavirus vaccine program for underinsured university
students along the United States/Mexico border. J Am Pharm Assoc.
2014;54(6):642-647. doi:10.1331/JAPhA.2014.13222
Stubbs BW, Panozzo CA, Moss JL, Reiter PL, Whitesell DH, Brewer NT.
Evaluation of an Intervention Providing HPV Vaccine in Schools. Am J Health
Behav. 2014;38(1):92-102. doi:10.5993/AJHB.38.1.10
Moss JL, Reiter PL, Truong YK, Rimer BK, Brewer NT. School Entry
Requirements and Coverage of Nontargeted Adolescent Vaccines. Pediatrics.
November 2016.
52

29.

30.
31.

32.

33.

34.
35.
36.

37.

38.
39.

40.

41.

http://pediatrics.aappublications.org/content/early/2016/11/05/peds.20161414.abstract.
Perkins RB, Lin M, Wallington SF, Hanchate AD. Impact of school-entry and
education mandates by states on HPV vaccination coverage : Analysis of the
2009 – 2013 National Immunization Survey-Teen. Hum Vaccin Immunother.
2016;12(6):1615-1622. doi:10.1080/21645515.2016.1150394
Potter RC, De Vita SF, Vranesich PA, Boulton ML. Adolescent immunization
coverage and implementation of new school requirements in michigan, 2010.
Am J Public Health. 2014;104(8):1526-1533. doi:10.2105/AJPH.2014.301910
Cassidy B, Braxter B, Charron-Prochownik D, Schlenk EA. A Quality
improvement initiative to increase HPV vaccine rates using an educational and
reminder strategy with parents of preteen girls. J Pediatr Heal Care.
2014;28(2):155-164. doi:10.1016/j.pedhc.2013.01.002
Paskett ED, Krok-Schoen JL, Pennell ML, et al. Results of a Multi-level
Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake
among Adolescent Girls. Cancer Epidemiol Biomarkers Prev. 2016;25(4):593602. doi:10.1158/1055-9965.EPI-15-1243
Patel DA, Zochowski M, Peterman S, Dempsey AF, Ernst S, Dalton VK.
Human Papillomavirus Vaccine Intent and Uptake among Female College
Students. J Am Coll Health. 2012;60(2):151-161.
doi:10.1080/07448481.2011.580028
Mazzoni SE, Brewer SE, Pyrzanowski JL, et al. Effect of a multi-modal
intervention on immunization rates in obstetrics and gynecology clinics. Am J
Obstet Gynecol. 2016;214(5):617e1-617e7. doi:10.1016/j.ajog.2015.11.018
Fiks AG, Grundmeier RW, Mayne S, et al. Effectiveness of Decision Support
for Families, Clinicians, or Both on HPV Vaccine Receipt. Pediatrics.
2013;131(6):1114-1124. doi:10.1542/peds.2012-3122
Moss JL, Reiter PL, Dayton A, Brewer NT. Increasing adolescent
immunization by webinar : A brief provider intervention at federally qualified
health centers. Vaccine. 2012;30(33):4960-4963.
doi:10.1016/j.vaccine.2012.05.042
Szilagyi PG, Albertin C, Humiston SG, et al. A randomized trial of the effect of
centralized reminder/recall on immunizations and preventive care visits for
adolescents. Acad Pediatr. 2013;13(3):204-213.
doi:10.1016/j.acap.2013.01.002
Sanderson M, Canedo JR, Khabele D, et al. Pragmatic trial of an intervention
to increase human papillomavirus vaccination in safety-net clinics. BMC Public
Health. 2017;17:158. doi:10.1186/s12889-017-4094-1
Aragones A, Bruno DM, Ehrenberg M, Tonda-Salcedo J, Gany FM. Parental
education and text messaging reminders as effective community based tools to
increase HPV vaccination rates among Mexican American children. Prev Med
Reports. 2015;2:554-558. doi:10.1016/j.pmedr.2015.06.015
Vaccination Programs: Client Reminder and Recall Systems. The Community
Guide. https://www.thecommunityguide.org/findings/vaccination-programsclient-reminder-and-recall-systems. Published 2015. Accessed December 25,
2019.
Rand CM, Brill H, Albertin C, et al. Effectiveness of centralized text message
reminders on human papillomavirus immunization coverage for publicly
insured adolescents. J Adolesc Heal. 2015;56(5):S17-S20.
doi:10.1016/j.jadohealth.2014.10.273
53

42.

43.

44.
45.
46.
47.

48.

49.
50.

51.

52.
53.

54.

55.

Suh CA, Saville A, Daley MF, et al. Effectiveness and Net Cost of
Reminder/Recall for Adolescent Immunizations. Pediatrics.
2012;129(6):e1437 LP-e1445.
http://pediatrics.aappublications.org/content/129/6/e1437.abstract.
Rand CM, Vincelli P, Goldstein NPN, Blumkin A, Szilagyi PG. Effects of
Phone and Text Message Reminders on Completion of the Human
Papillomavirus Vaccine Series. J Adolesc Heal. 2017;60(1):113-119.
doi:10.1016/j.jadohealth.2016.09.011
Kempe A, O’Leary ST, Shoup JA, et al. Parental Choice of Recall Method for
HPV Vaccination: A Pragmatic Trial. Pediatrics. 2016;137(3):e20152857e20152857. doi:10.1542/peds.2015-2857
Chung RJ, D M, Walter EB, et al. Keen on Teen Vaccines : Improvement of
Adolescent Vaccine Coverage in Rural North Carolina. J Adolesc Heal.
2015;56(5):S14-S16. doi:10.1016/j.jadohealth.2014.10.272
Bar-Shain DS, Stager MM, Runkle AP, Leon JB, Kaelber DC. Direct
messaging to parents/guardians to improve adolescent immunizations. J
Adolesc Heal. 2015;56(5):S21-S26. doi:10.1016/j.jadohealth.2014.11.023
Vaccination Programs: Community-Wide Education When Used Alone. The
Community Guide. https://www.thecommunityguide.org/findings/vaccinationprograms-community-wide-education-when-used-alone. Published 2019.
Accessed January 13, 2020.
Vaccination Programs: Clinic-Based Client Education when Used Alone. The
Community Guide. https://www.thecommunityguide.org/findings/vaccinationprograms-clinic-based-client-education-when-used-alone. Published 2019.
Accessed January 13, 2020.
Groom HC, Irving SA, Caldwell J, et al. Implementing a Multipartner HPV
Vaccination Assessment and Feedback Intervention in an Integrated Health
System. 2017;23(6):589-592. doi:10.1097/PHH.0000000000000562
Hohmeier KC, Randolph DD, Smith CT, Hagemann TM. A multimodal
approach to improving human papillomavirus vaccination in a community
pharmacy setting. SAGE Open Med. 2016;4:1-5.
doi:10.1177/2050312116682128
Jiménez-quiñones EM, Melin K, Pharmd FJJ. Impact of a Pharmacist
Conducted Educational Program on Human Papilloma Virus Vaccination Rates
in a Low Socioeconomic Population in the City of Lares, PR. Puerto Rico Heal
Sci J. 2017;36(2):67-70.
Rickert VI, Auslander BA, Cox DS, Rosenthal SL, Rupp RE, Zimet GD.
School-based HPV immunization of young adolescents : Effects of two brief
health interventions. Hum Vaccin Immunother. 2015;11(2):315-321.
Staras SAS, Vadaparampil ST, Livingston MD, Thompson LA, Sanders AH,
Shenkman EA. Increasing Human Papillomavirus Vaccine Initiation among
Publically-Insured Florida Adolescents. J Adolesc Health. 2015;56(0):S40-S46.
doi:10.1016/j.jadohealth.2014.11.024
Karanth SS, Lairson DR, Huang D, Savas LS, Vernon SW, Fernández ME. The
cost of implementing two small media interventions to promote HPV
vaccination. Prev Med (Baltim). 2017;99:277-281.
doi:10.1016/j.ypmed.2017.03.002
Vaccination Programs: Requirements for Child Care, School, and College
Attendance. https://www.thecommunityguide.org/findings/vaccination-

54

56.

57.

58.
59.
60.

61.
62.

63.
64.

65.

66.
67.

68.

programs-requirements-child-care-school-and-college-attendance. Published
2016. Accessed January 3, 2020.
Vaccination Programs: Provider Assessment and Feedback. The Community
Guide. https://www.thecommunityguide.org/findings/vaccination-programsprovider-assessment-and-feedback. Published 2015. Accessed January 13,
2020.
Perkins RB, Zisblatt L, Legler A, Trucks E, Hanchate A, Gorin SS.
Effectiveness of a provider-focused intervention to improve HPV vaccination
rates in boys and girls. Vaccine. 2015;33(9):1223-1229.
doi:10.1016/j.vaccine.2014.11.021
Vaccination Programs: Provider Reminders. The Community Guide.
https://www.thecommunityguide.org/findings/vaccination-programs-providerreminders. Published 2015. Accessed December 25, 2019.
Szilagyi PG, Serwint JR, Humiston SG, et al. Effect of Provider Prompts on
Adolescent Immunization Rates : A Randomized Trial. Acad Pediatr.
2015;15(2):149-157. doi:10.1016/j.acap.2014.10.006
Vaccination Programs: Reducing Client Out-of-Pocket Costs. The Community
Guide. https://www.thecommunityguide.org/findings/vaccination-programsreducing-client-out-pocket-costs. Published 2014. Accessed December 25,
2019.
Eldred S V, Hamid HS, Snider JC, et al. A Medical Student-Driven “Vaccine
Blitz” at a School-Based Health Center as an Effective Way to Improve
Adolescent Vaccination Rates. Fam Med. 2015;47(7):546-548.
Richman AR, Maddy L, Torres E, Goldberg EJ. A randomized intervention
study to evaluate whether electronic messaging can increase human
papillomavirus vaccine completion and knowledge among college students. J
Am Coll Heal. 2016;64(4):269-278.
Tiro JA, Sanders JM, Pruitt SL, et al. Promoting HPV Vaccination in SafetyNet Clinics: A Randomized Trial. Pediatrics. 2015;136(5):850 LP - 859.
http://pediatrics.aappublications.org/content/136/5/850.abstract.
Vanderpool RC, Breheny PJ, Tiller PA, et al. Implementation and Evaluation
of a School-Based Human Papillomavirus Vaccination Program in Rural
Kentucky. Am J Prev Med. 2015;49(2):317-323.
doi:10.1016/j.amepre.2015.05.001
McLean HQ, VanWormer JJ, Chow BDW, et al. Improving Human
Papillomavirus Vaccine Use in an Integrated Health System: Impact of a
Provider and Staff Intervention. J Adolesc Heal. 2017;61(2):252-258.
doi:10.1016/j.jadohealth.2017.02.019
Jacobs-Wingo JL, Jim CC, Groom A V. Human Papillomavirus Vaccine
Uptake: Increase for American Indian Adolescents, 2013–2015. Am J Prev
Med. 2017;53(2):162-168. doi:10.1016/j.amepre.2017.01.024
Zimmerman RK, Moehling KK, Lin CJ, et al. Improving adolescent HPV
vaccination in a randomized controlled cluster trial using the 4 Pillars TM
practice Transformation Program. Vaccine. 2017;35(1):109-117.
doi:10.1016/j.vaccine.2016.11.018
Farmar A-LM, Love-Osborne K, Chichester K, Breslin K, Bronkan K,
Hambidge SJ. Achieving High Adolescent HPV Vaccination Coverage.
Pediatrics. 2016;138(5):e20152653. doi:10.1542/peds.2015-2653

55

69.
70.

Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational
interventions to increase HPV vaccination acceptance: A systematic review.
Vaccine. 2014;32(17):1901-1920. doi:10.1016/j.vaccine.2014.01.091
Niccolai LM, Hansen CE. Practice- and Community-Based Interventions to
Increase Human Papillomavirus Vaccine Coverage: A Systematic Review.
JAMA Pediatr. 2015;169(7):686-692. doi:10.1001/jamapediatrics.2015.0310

56

JOURNAL ARTICLE-2
A cost-effectiveness analysis of HPV vaccine promotion interventions
American Journal of Preventive Medicine
Background
Human papillomavirus (HPV) vaccines have proven capable of substantially
reducing the risk of cervical cancer. However, HPV vaccine coverage in the U.S. has
been relatively low. From the latest data of HPV vaccine coverage in the U.S., 53.7%
of girls aged 13-17 years old were up to date with HPV vaccine series in 2018. 1 This is
significantly below the CDC’s Healthy People target of 80% coverage by 2020 . By
comparison to rates in other developed countries, the HPV vaccine coverage rate in
Australia among females at age 15 reached to 85% in 2017.2 The HPV vaccine coverage
in the United Kingdom among females aged 12-13 years was 90% in 2018. 3 Given that
the coverage rate is sub-optimal in the U.S., improving HPV vaccine coverage is a
consequential public health issue. Implementing interventions designed to promote the
HPV vaccine is the main approach to increasing HPV vaccine coverage in the U.S. The
Community Preventive Services Task Force (the Community Guide) identified a
number of strategies for increasing vaccine coverage. Strategies include home visits,
school requirements, patient reminder and recall system, provider assessment and
feedback, provider reminders, standing orders, reducing client out-of-pocket costs,
immunization information systems, school-based vaccine programs, community-based
intervention combination, and health care system-based interventions.4 However, the
cost-effectiveness of implementing such interventions remains unknown. Resources
required of implementing interventions varied and the cost-effectiveness is an
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important consideration. The aim of this study was to assess the cost-effectiveness of
interventions designed to increase HPV vaccine coverage in the U.S.
Methods
We assessed the cost-effectiveness of several U.S. HPV vaccine promotion
interventions versus current practice. The data for both cost and effectiveness were
derived from relevant published literature. The HPV vaccine is recommended for
individuals at ages 11-12; the vaccine can be given as early as age 9. 5 Our focus for
included literature is on the age of 9 to 12 years old. In our previous systematic review
study, we have identified interventions used to improve the HPV vaccine coverage,
including patient reminder and recall system, patient education, provider assessment
and feedback, provider reminders, standing orders, reducing client out-of-pocket costs,
immunization

information

systems,

school-based vaccine

programs,

school

requirements, community-based intervention combination, and health care systembased interventions. Interventions if either cost or effectiveness are not available in the
literature were excluded. After identifying evidence of intervention costs and
effectiveness, we included patient reminder and recall system, patient education,
provider reminders, reducing patient out-of-pocket costs, school-based vaccine
programs, and community-based intervention combinations in the evaluation. The
primary outcome measures for this study were incremental cost-effectiveness ratios
(ICERs), which were computed by the following equation.
ICER =
ICERs represented the cost per additional intervention individuals that completed the
HPV vaccine series, compared with current practice. A secondary analysis was
conducted in which the effectiveness of ICERs was measured by the percentage
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increase of receiving at least one HPV vaccine dose of interventions. The secondary
analysis ICER was computed by the following equation.
ICER =
ICERs of secondary analysis represented the cost per additional intervention individual
that received at least one HPV vaccine dose. To address the issue of the parameter
uncertainty, sensitivity analysis was performed. We varied the cost and effectiveness
for the HPV vaccine promotion intervention with plausible estimates derived from
published literature.
Effectiveness estimation
The HPV vaccine series completion rate of the intervention was computed by the
percentage change of completing the HPV vaccine series between intervention and
control groups. The outcome of receiving at least one HPV vaccine dose was measured
by the percentage change of receiving at least one HPV vaccine dose between
intervention and control groups. The HPV vaccine completion rate for the patient
reminder and recall system was derived from a study of Kaiser Permanente Southern
California Health Plan female members aged 9-26 years old. They found the HPV
vaccine series completion rates were 56% and 46% in the intervention and control
groups, respectively.6 Data for receiving at least one HPV vaccine dose was derived
from a study in which text message reminders for the next needed HPV vaccine doses
were sent to parents of adolescents aged 9 to 20 years old. Percentages of receiving at
least one HPV vaccine dose were 52% and 35% in the intervention and control groups,
respectively.7
We identified 16 studies that used patient education to increase HPV vaccine
coverage. Only 4 studies among them reported the percentage change of HPV vaccine
series completion rate between intervention and control groups.8–11 Since 4 studies all
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focused on a specific population (e.g. Appalachian or African American and Hispanic
females), we applied a median change of 6% among studies in the base-case analysis
(range of values: -6% to 25%). We found 10 patient education interventions that
measured percentage changes for receiving at least one dose of HPV vaccine. Among
them, 2 studies (including 10 intervention arms) were implemented in our age group.
The remaining interventions were excluded because they were implemented in either
an age group which was older than 12 years old or a specific population (e.g. AfricanAmerican or Haitian American females). We applied a median change of 2% among
studies in the base-case analysis (range of values: -3% to 4%). 12,13
The HPV vaccine completion rate of provider reminder was estimated from a
randomized controlled trial in which they assessed immunization rates on provider
prompts at health care visits among 11-17 years old adolescents. They found HPV
vaccine completion rates were 50% and 42% in the intervention and control groups,
respectively14. Data on percentages receiving at least one dose HPV vaccine of provider
reminders were not available in the literature. We used information published by the
Community Guide that they reviewed interventions by using provider reminders to
increase immunization rates (eg. influenza or pneumococcal). They concluded that an
overall median increase of immunization rate for the provider reminder is 10%.15
We identified 3 studies that used interventions designed to reduce out-of-pocket
costs to increase HPV vaccine coverage. In the 3 studies, outcomes of HPV vaccination
rates were measured before and after the intervention among females older than 18
years old. We applied the result from Moore et al. study for the HPV vaccine
completion rate since it was the only study that reported the completion rate. The study
offered free 3-dose HPV vaccine for females aged 18 to 24 years old. After the
intervention, about 28% of participants completed the series of HPV vaccination. 16Data
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on percentages receiving at least one dose HPV vaccine of the intervention were derived
from a study in which an HPV vaccine voucher was offered to redeem the 3 dose HPV
vaccine series without a charge among 247 Appalachian women. After the intervention,
45% of the study participants redeemed the coupon to receive the first dose of HPV
vaccine.17
Information on the HPV vaccine completion rate of school-based vaccine
programs was not available from the literature. Therefore, we used the alternative
effectiveness measurement of HPV vaccine initiation rate in the analysis. Data on the
HPV vaccine initiation rate were derived from a study of school-located HPV
vaccination clinics for middle school girls. They found that HPV vaccine initiation rates
were higher among intervention schools than control schools (6% vs. 1%). 18 Data on
the percentage of receiving at least one dose of HPV vaccine were derived from a study
that assessed the impact on a school-located adolescent vaccination program in Denver
public schools. Sixteen Denver public schools were eligible to participate in the study
and were randomly assigned as intervention (n=8) and control schools (n=8).
Intervention schools conducted school-located vaccination programs among 6 th to 8thgrade students; whereas control schools did not. The HPV vaccine initiation rate among
students needing a vaccine was higher in the intervention schools than control schools
(20% vs. 7%) among 7th and 8th-grade female students.19
The community-based intervention combination combined patient reminder and
recall system and patient education. Data for effectiveness was derived from a
randomized controlled trial that evaluated effects of a multicomponent intervention
including HPV vaccine brochure and recalls among girls aged 11 to 18 years old
attending the pediatric clinic. They found that patients in the intervention groups were
more likely to receive all 3 doses after the intervention compared with the control group
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(28% vs. 15%, respectively).20 Data on the percentage of receiving at least one dose
HPV vaccine were derived from a study in which they assessed the effect of the
educational brochure and a reminder system on the HPV vaccine uptake rate among
eligible 11 to 12 years old girls. HPV vaccine uptake rates in the intervention and
control groups were 75% versus 24%21.
We assumed the current practice strategy would include the provision of standard
HPV vaccine information sheets to the target population. The effectiveness of current
practice was computed by the percentage change of the HPV vaccine coverage in the
control group during the study period. Data on the effectiveness of current practice was
derived from a study of adolescents aged 11 to 17 years old. Individuals in the control
group received standard of care. They found that HPV 3 doses vaccination rate was
51% at baseline and increased to 53% at the end of the study period in the control
group.14
Cost estimation
Costs were measured as intervention costs per person. Costs of administering the
HPV vaccine such as physician fees and vaccine costs were excluded since we focused
on getting the eligible participants to the point of choosing to be vaccinated, and not the
cost-effectiveness of the vaccine which has been confirmed in several previous studies.
All costs were adjusted to 2018 USD using the Consumer Price Index from the U.S.
Bureau of Labor Statistics 22.
Costs of patient reminder and recall systems were estimated from Szilagyi et al.
study. They conducted a randomized controlled trial to evaluate a managed care-based
patient reminder and recall system. The intervention costs were $23 and $21 per
adolescent for mailed letters and telephone reminders, respectively. We applied the
mean value in base-case analysis 23.
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Costs of patient education were derived from a study of print-based photonovella
and iPad-based tailored interactive multimedia interventions (TIMI) to promote the
HPV vaccine ($73 vs. $90). Costs documented in the study included personnel,
material, overhead and participant time cost for the intervention. We excluded overhead
and participant time costs since those data were not available for other interventions. 24
Costs for both the provider reminder and the community-based intervention
combination were not available in the HPV vaccine promotion intervention literature.
Their cost estimates were derived from reports published by the Community Guide that
systematically reviewed studies on immunization promotion interventions (eg.
influenza or pneumococcal). Cost ranges for the provider reminder and the communitybased intervention combination were $2 to $54 and $16 to $250 per person,
respectively. We applied the mid-points of ranges ($28 and $133 for provider reminder
and community-based intervention combination, respectively) in the base-case analysis
and addressed the uncertainty in the sensitivity analysis.15,25
The cost of school-based vaccine programs was derived from a school-located
adolescent vaccination program study. They reported that the cost of administering the
program per vaccine dose was $30 and a total of 1,505 vaccine doses were administered
among 527 students who consented to participate in the intervention. We estimated the
intervention cost was $85 per participant.19
The cost data for reducing patients’ out-of-pocket costs were not available from
the literature. We assumed the cost of implementing the intervention is the sum for
providing 3-dose HPV vaccinations ($178/ per dose per participant) 26 plus the material
and personnel cost for implementing the intervention ($41/ per participant) 27.
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We estimated costs of current practice were $3 per person, which is based on the
printing and office costs of HPV vaccine information sheets derived from a study of
clinic-based media intervention to promote HPV vaccination. 24
Results
Parameters of cost and effectiveness used in the base-case and sensitivity analysis
were presented in Table 4. Intervention costs ranged from $22 per individual (patient
reminder and recall system) to $575 per individual (reducing out-of-pocket costs). For
the effectiveness of interventions, the increase in HPV vaccine completion rate ranged
from 5% (school-based vaccine programs) to 28% (reducing out-of-pocket costs). For
the percentage increase of receiving at least one dose HPV vaccine, effectiveness
ranged from 2% (patient education) to 51% (community-based vaccination
combinations). Under base-case analysis when intervention effectiveness was
measured by the increase of HPV vaccine completion rate, the cost per additional
individual completed HPV vaccine series for the patient reminder and recall system
was $238 compared with current practice (Table 5). Interventions of provider reminder,
patient education, and school-based vaccine programs were dominated by patient
reminder and recall system since they have higher costs but lower effectiveness than
patient reminder and recall system. The community-based intervention combination
was extended dominance since its ICER is greater than that of the reducing out-ofpocket costs intervention. The ICER of reducing out-of-pocket costs is $3,072,
compared with patient reminder and recall system.
In the secondary analysis when the intervention effectiveness was measured by the
percentage increase of receiving at least one HPV vaccine dose, the cost per additional
individual received at least one HPV vaccine for the patient reminder and recall system
was $107, compared with current practice. Provider reminder, patient education and
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school-based vaccine programs were dominated by the patient reminder and recall
system. The ICER of the community-based intervention combinations was $326,
compared with the patient reminder and recall system. Reducing out-of-pocket costs
were dominated by the community-based intervention combinations which has a lower
cost but yields a better outcome on the percentage of receiving at least one dose HPV
vaccine.
Parameters for both cost and effectiveness for the HPV vaccine promotion
intervention varied in the sensitivity analysis with plausible estimates derived from
published literature. Results for the one-way sensitivity analysis shown in the tornado
diagram in Figure 7. Overall, intervention effectiveness has a greater impact on the
ICER than varying the cost estimates. We examined the “best-case (the lowest cost and
the highest effectiveness)” and “worst-case (the highest cost and the lowest
effectiveness)” scenarios in the multiple-way sensitivity analysis (Table 7). In the bestcase scenario, the most cost-effective intervention remained the patient reminder and
recall system. In the worst-case scenario, the most cost-effective was provider
reminder. The ICER of the provider reminder was $933 when compared with current
practice.
Discussion
In the U.S., HPV vaccine coverage is suboptimal. Various interventions have been
designed to improve coverage. In our previous systematic review study, we have
identified interventions used to improve the HPV vaccine coverage, including patient
reminder and recall system, patient education, provider assessment and feedback,
provider reminders, standing orders, reducing client out-of-pocket costs, immunization
information

systems,

community-based

school-based

intervention

vaccine

combination,
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programs,
and

health

school

requirements,

care

system-based

interventions. The consideration of cost-effectiveness of these interventions are
important. However, there is limiter evidence on the cost-effectiveness of HPV vaccine
promotion interventions. To our knowledge, this is the first economic evaluation
assessing a range of HPV vaccine promotion interventions in the US. It provides
decision-makers evidence-based information and analysis of uncertainty about
interventions aimed to improve HPV vaccine coverage.
We found that patient reminder and recall system was the most cost-effective
intervention when the intervention effectiveness was measured as either the increase of
HPV vaccine series completion rates or the percentage of patients receiving at least one
dose of the HPV vaccine. The cost per additional individual that completed the HPV
vaccine series and the cost per additional individual received at least one dose of HPV
vaccine for the patient reminder and recall system were $238 and $107, respectively.
Provider reminder interventions of, patient education and vaccination program in
schools were dominated by the patient reminder and recall system, which is both more
effective and less expensive. Patient reminder and recall system was one of the
interventions recommended by the Community Guide in increasing vaccine coverage.
The Guide concluded that patient reminder and recall systems can be implemented for
a large number of patients and achieve vaccinations with relatively few economic
resources.28 The intervention designed to reduce patient out-of-pocket costs and
community-based intervention combinations were more effective in increasing HPV
vaccination rates than the patient reminder and recall system but substantially increased
the intervention cost per individual. Decision-makers need to consider the cost
structure, the applicability of interventions (e.g. different population or settings) and
their willingness to pay for implementing the interventions to determine which
intervention would be justified and feasible.
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There are uncertainties of cost and effectiveness parameters that exist in our study
since evidence regarding the cost-effectiveness of HPV vaccine promotion intervention
was little. To evaluate our parameter estimates, we used literature focusing on other
immunization promotion interventions to discuss similarities and differences in results
(Table 8).29,30 The effectiveness of HPV vaccine promotion interventions including
patient reminder and recall system, provider reminder, interventions designed to reduce
patient out-of-pocket costs and community-based intervention combinations were
similar to interventions intended to increase other immunizations. Vaccination
programs in schools aimed to promote HPV vaccine have lower effectiveness,
compared with interventions intended to increase other immunization coverage.
Evidence on HPV vaccine coverage rates increased by the vaccination program in
schools was limited. More research is needed to determine intervention effectiveness
of school-based programs. For the effectiveness of patient education, it is challenging
to compare the effectiveness of the HPV vaccine and other immunizations due to
inconsistent results. The Community Guide finds insufficient evidence to determine the
effectiveness of patient education. In the Briss et al. systematic review, the effectiveness
of patient education has a wide range, ranging from -4% to 29%. Patient education is
the most common approach to increase HPV vaccine coverage. Since there are many
different ways of implementing patient education, it is challenging to determine the
effectiveness across a range of delivery methods (e.g., person-to-person interactions,
clinic-based educations, and mass or small media). Future studies should develop a
more detailed category system of patient education in order to better quantify the
impact. For the intervention cost, patient reminder and recall system used to improve
HPV vaccine cost more, compared with other immunizations. Identifying cost evidence
in the literature is challenging since cost measurements reported in the literature were
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not our outcome of interest. We identified 7 studies that reported intervention costs.
Two of them reported intervention costs per participant were included in our analysis.
The remaining reported different cost estimates (e.g. cost per reminder sent, cost per
intervention practice and total cost of intervention) and we included in our analysis if it
is feasible to convert their cost outcome by using study information. The cost of
implementing interventions is important information for the intervention planner. More
evidence on intervention cost is needed in the future.
There are several limitations to this study. Firstly, the percentage change of HPV
vaccine series completion rates of patient education derived from studies that focused
on specific populations (e.g., Appalachian or African American and Hispanic females).
Interventions were implemented in groups that may not be representative of findings in
the general population. We performed a subgroup analysis which included
interventions implemented among the specific populations (Table 6). Interventions of
patient reminder and recall system, patient education, intervention combinations and
reducing out-of-pocket costs were included in the subgroup analysis. Intervention
combinations was the most cost-effective when we focused on the specific population.
More data is needed to understand CEA results of interventions implemented in the
specific population. Data on both the percentage change of receiving at least one dose
HPV vaccine of provider reminder and HPV vaccine completion rate for the schoolbased vaccine programs were not available in the literature. For the percentage change
of receiving at least one dose HPV vaccine of provider reminder, we used results from
the Community Guide reports. They synthesized evidence of interventions intended to
increase other immunizations, rather than the HPV vaccine. For the HPV vaccine
completion rate for the vaccination program in schools, we used the HPV vaccine
initiation rate in the base-case analysis. The effectiveness of school-based vaccine
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programs might be overestimated since visits are needed to complete the HPV vaccine
series. The analysis should be updated when data become available on school-based
programs. Secondly, the costs of both the provider reminder and community-based
intervention combinations intended to increase HPV vaccine coverage were not
available from the literature. We estimated the effectiveness of community-based
interventions from the Community Guide which reviewed interventions intended to
improve other vaccinations, such as influenza or pneumococcal vaccinations.
Sensitivity analyses were performed to address uncertainties in the estimates. When we
varied parameters with the lowest costs and highest effectiveness (best-case scenario),
patient reminder and recall system remained the most cost-effective intervention. In the
worst-case scenario, patient reminder and recall system was dominated by current
practice. Provider reminder was the most cost-effective intervention under the worstcase scenario.
Conclusion
We assessed the cost-effectiveness of several U.S. HPV vaccine promotion
interventions versus current practice. Interventions of patient reminder and recall
system, patient education, provider reminders, reducing patient out-of-pocket costs,
school-based vaccine programs, and community-based intervention combinations were
included in the evaluation. We found that patient reminder and recall system is the most
cost-effective HPV vaccine promotion interventions. The cost per additional individual
completed HPV vaccine series (ICER) was $238. When the intervention effectiveness
was measured as the percentage change of receiving at least one dose HPV vaccine, the
ICER for the patient reminder and recall system was $107.
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Table 4. Costs and effectiveness for HPV vaccine promotion interventions.
Intervention
Cost a Cost range
Effectiveness (1) b Effectiveness (2) c Effectiveness range
21
21
Current practice
$3
0~$6
+2%12
+2%12
NA
20
25
d
6
7
Patient reminder and recall system
$22
$2 ~$33
+10%
+17%
028~+25%29
21
e
21
8–11
30
Patient education
$73
$37 ~$90
+7%
+2%
027~+25%10
13
13
13
12
13
Provider reminder
$29
$8 ~$62
+8%
+10%
+8%12~+17%27
16
e
d
15
16
Vaccination programs in schools
$85
$43 ~$128
+5%
+13%
+5%15~+41%31
Reducing out-of-pocket costs
$57532 $4021~$72432,33
+28% 34
+45%14
+10%27~+45%14
f
22
22
22
17
18
Intervention combinations
$133
$63 ~$313
+13%
+51%
+2%35~+56%18
a: Measured as cost per participant of the intervention
b: Measured as the percentage change of the HPV series completion rate between intervention and control groups
c: Measured as the percentage change of receiving at least one HPV dose between intervention and control groups
d: Information were not available in the literature. We assumed the highest cost of the intervention is the base-case value times 1.5
e: Information were not available in the literature. We assumed the lowest cost of the intervention is the base-case value times 0.5
f: Intervention combined patient reminder and recall system and patient education

70

Table 5. Base-case results of CEA for the HPV vaccine promotion interventions
Incremental
Incremental
ICER
Strategya
Cost
cost
Effectiveness Effectiveness
Primary outcome: Effectiveness was measured as the percentage change for the HPV vaccine series completion rate
between intervention and control groups
Current practice
$3
+2%
Patient reminder and recall system
$22
$19
+10%
+8%
$238
Provider reminder
$29
$7
+8%
-2%
Dominated
Patient education
$73
$51
+7%
-3%
Dominated
Vaccination programs in schools
$85
$63
+5%
-5%
Dominated
Intervention combinations
$133
$111
+13%
+3%
Extended dominance
Reducing out-of-pocket costs
$575
$553
+28%
+18%
$3,072
Secondary outcome: Effectiveness was measured as the percentage change for receiving at least one HPV vaccine dose
between intervention and control groups
Current practice
$3
+2%
Patient reminder and recall system
$22
$16
+17%
+15%
$107
Provider reminder
$29
$32
+10%
-7%
Dominated
Patient education
$73
$51
+2%
-15%
Dominated
Vaccination programs in schools
$85
$63
+13%
-4%
Dominated
Intervention combinations
$133
$111
+51%
+34%
$326
Reducing out-of-pocket costs
$575
$442
+45%
-6%
Dominated
a: Interventions were order from highest to lowest costs
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Table 6. CEA for the HPV vaccine promotion intervention among specific populations
Incremental
Strategya
Cost
cost
Effectiveness
24
Current practice
$3
+2%14
23
Patient reminder and recall system
$22
$19
+5%23
Patient education
$7324
$55
+7%8–11
25
Intervention combinations
$133
$130
+25%37
Reducing out-of-pocket costs
$57534
$442
+36%17
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Incremental
Effectiveness
+3%
+2%
+23%
+11%

ICER
Extended dominance
Extended dominance
$565
$4018

Figure 7. Tornado diagram of the one-way sensitivity analysis: comparisons between HPV vaccine promotion interventions and current practice
Effectiveness for reducing out-of-pocket costs (10% to 45%)
Effectiveness for patient education (0 to 25%)
Costs for vaccination programs in schools ($43 to $128)
Costs for reducing out-of-pocket costs ($40 to $724)
Costs for intervention combinations ($63 to $313)
Effectiveness for vaccination programs in schools (5% to 41%)
Costs for patient education ($37 to $90)
Effectiveness for patient reminder and recall system (0 to 25%)
Costs for provider reminder ($8 to $62)
Costs for patient reminder and recall system ($2 to $33)
Effectiveness for provider reminder (8% to 17%)
Effectiveness for intervention combinations (2% to 56%)
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Table 7. Results of the multiple-way sensitivity analysis for HPV vaccine promotion interventions in the CEA
Incremental
Incremental
ICER
Strategya
Cost
cost
Effectiveness Effectiveness
The best-case scenario: the lowest costs and highest effectiveness for HPV vaccine promotion interventions
Current practice
0
+2%
Patient reminder and recall system
$2
$2
+25%
+23%
$9
Provider reminder
$8
$6
+17%
-8%
Dominated
Patient education
$37
$35
+25%
0
Dominated
Reducing out-of-pocket costs
$40
$38
+45%
+20%
$190
Vaccination programs in schools
$43
$3
+41%
-4%
Dominated
Intervention combination
$63
$23
+56%
+11%
$209
The worst-case scenario: the highest costs and lowest effectiveness for HPV vaccine promotion interventions
Current practice
$6
+2%
Patient reminder and recall system
$33
$27
0
-2%
Dominated
Provider reminder
$62
$56
+8%
+6%
$933
Patient education
$90
$28
0
-8%
Dominated
Vaccination programs in schools
$128
$66
+5%
-3%
Dominated
Intervention combination
$313
$251
+2%
-6%
Dominated
Reducing out-of-pocket costs
$724
$662
+10%
+2%
$33,100
a: Interventions were order from highest to lowest costs
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Table 8. Comparisons with the cost and effectiveness results with literature reviewing immunization promotion interventions
Strategy
Effectiveness
Cost
The Community Guide
Briss et al. (2000)
The Community Guidea
Briss et al. (2000)
Patient reminder and recall
Vaccination rates
Vaccination rates
Median cost per person
$0.65 to $5.75 per child
system
increased by a median of increased by a median of per year of $2.43
11 percentage points
12 percentage points
(median increase of 6
(median increase of 8
and 12 percentage points and 16 percentage points
when used alone and
when used alone and
with additional
with additional
components,
components,
respectively)
respectively)
Patient education
Insufficient evidence to
Percentage point changes No economic evidence
No evidence on cost per
determine the
in vaccination coverage
person reported
effectiveness
ranged from -4% to
29%b
Provider reminder
Vaccination rates
Vaccination rates
Median cost per person
No evidence on cost per
increased by a median of increased by a median of per year of $7.98
person reported
10 percentage points
17 percentage points
(median increase of 12
(median increase of 17
and 9 percentage points
and 14 percentage points
when used alone and
when used alone and
with additional
with additional
components,
components,
respectively)
respectively)
Vaccination programs in
Vaccination rates
No evidence on
No economic evidence
No economic evidence
schools
increased by a median of percentage point change
41 percentage points
on vaccination rates
reported
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Reducing out-of-pocket costs

Vaccination rates
Vaccination rates
Median cost per person
increased by a median of increased by a median of per year of $50.74
22 percentage points
15 percentage points
(median increase of 28
(median increase of 10
and 20 percentage points and 16 percentage points
when used alone and
when used alone and
with additional
with additional
components,
components,
respectively)
respectively)
Community-based intervention Vaccination rates
No evidence reported
Median cost per person
combinations c
increased by a median of
per year of $63.08
16 percentage points
a: costs were updated to year of 2018
b: data were derived from multiple components interventions which included patient education
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No evidence on cost per
person reported

No evidence reported
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JOURNAL ARTICLE-3
A Cost-utility analysis of implementing the HPV vaccine promotion
interventions of cervical cancer
Vaccine
Background
Human papillomavirus (HPV) vaccines have been proven capable of
substantially reducing the risk of cervical cancer. Between 2012 and 2016, the average
annual number of diagnosed HPV-associated cervical cancers in the U.S. was 12,015.
Of these cases, an estimated 9,700 (81%) were attributable to the cancer types targeted
by the 9 valent HPV vaccine.1 According to an economic evaluation of the HPV
vaccine, researchers concluded that HPV vaccination is cost-effective for cancer
prevention in comparison to the current standard prevention strategy.2 Regrettably,
HPV vaccine coverage in the U.S. has remained relatively low. According to recent
data estimating the vaccine’s coverage, the up-to-date coverage in 2017 was only 48.6%
among adolescents aged 13-17 years.3 This rate of coverage is far below the CDC’s
Healthy People target of 80% coverage by 2020. Intervention strategies designed to
promote the HPV vaccine are the main approach to increasing its overall coverage.
However, the cost-effectiveness of implementing HPV vaccine promotion
interventions has remained unknown. In this study, we conducted an economic
evaluation to assess interventions designed to increase HPV vaccine coverage in the
United States.
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Methods
A CUA was conducted which compared the following HPV vaccine promotion
interventions versus current practice: 1) patient reminder and recall system, 2) patient
education, 3) provider reminder, 4) vaccination program in schools, 5) reducing out-ofpocket costs and 6) intervention combination (patient reminder and recall system and
patient education). Current practice was defined that no particular intervention is
implemented to improve the vaccination rate. Consolidated health economic evaluation
reporting standards (CHEERS) was used as a guideline for conducting the health
economic study. The CHEERS checklist was presented in table 9. The target population
of this study was all adolescent girls in the U.S. Societal perspectives were applied in
the study. A Markov model was used to simulate the natural history of cervical cancer.
Markov model has been proven to be able to represent the natural history of cervical
cancer appropriately and adequately address the decision problem of the HPV
vaccination program.4,5 We followed a cohort of women starting at age 12 until all of
them died. The catch-up HPV vaccine through age 26 was added to the model. Health
states and allowed transitions between health states are presented in Figure 8. The
health outcome modeled in the study was quality-adjusted life-years (QALYs). All
costs were then updated to 2018 USD using the Medical Care Component of the
Consumer Price Index.

6

We followed the recommendation of the Panel on Cost-

Effectiveness in Health and Medicine for applying 3% discount rates to both costs and
utilities.

7

The outcome of the study was ICER, which was computed based on the

following formula:
ICER =
81

The half-cycle correction was applied for the model adjustment. We performed the
sensitivity analysis to address uncertainties. In the probabilistic sensitivity analysis
(PSA), main input parameters were changed and ran 1000 Monte-Carlo simulations
with sampling from defined distributions. Gamma distributions were applied to the
incidence rates of HPV infections and cervical cancer treatment costs. The standard
error of the parameters was defined as 10% of the point estimates. Beta distribution was
applied to the utility weights of the cancer stages and the standard error of the
parameters was defined as 25% of the point estimates.8 Models were analyzed using
TreeAge Pro decision frameworks (TreeAge Software, 2018).
In Figure 8, the node below the boxed intervention options represents the
vaccination decision following the implementation of an intervention. A natural history
of cervical cancer thereafter is simulated using a Markov model. Each year, women are
at risk of developing high-risk types of HPV infection, low-grade or high-grade
squamous intraepithelial lesions (LSIL and HSIL), or cervical cancer. Once a person is
infected with HPV, the conditions could regress to negative HPV infection or progress
to either LSIL or HSIL. Females can develop cervical cancer from high-grade SIL and
progress to invasive local cervical cancer, regional invasive cervical cancer, and distant
invasive cervical cancer. In this analysis, cancer cases are treated if detected. After
successful treatment, those cases are moved to the cancer survivors compartment, and
regression from cancer to normal is not allowed 5,9.
Model parameters
Model parameters were derived from the published literature (Table 10). We used
U.S. data for our parameters as much as possible to better reflect the realities. Each
cycle is assumed to be one year. Death rates for females without cervical cancer were
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obtained from Vital Statistics data.10 Summaries of data sources for parameters used in
the base-case analysis are described below, including HPV vaccine intervention costs
and effectiveness, HPV vaccine cost and coverage, HPV infections, LSIL and HSIL,
cervical cancer, cancer costs, and utilities.
HPV vaccine intervention costs and effectiveness
Costs and effectiveness of HPV vaccine promotion intervention were measured as
intervention costs per person and HPV vaccine series completion rates, respectively.
The data for both cost and effectiveness were derived from relevant published literature.
Rationales on intervention cost and effectiveness data selections have been described
in the aim 2 method section.
HPV vaccine cost and coverage
The cost for the HPV vaccine per dose is $203, which is the average of the
public and private costs 11. Cost (2018 year) for the administration fee and supply and
patient time are assumed $8.65 and $34.60, respectively

12

. The cost for the HPV

vaccine per 3 doses is assumed as $739 in the base-case, which includes 3 doses vaccine
fee, administration and patient time cost. The HPV vaccine cost in the public and
private sector were used to estimate the range of the HPV vaccination ($664 to $814).
The annual probabilities of HPV vaccination coverage among 12 to 26-year-old females
were derived from the CDC’s Morbidity and Mortality Weekly Report and Chesson et
al. (2019) study. In both studies, they used the National Immunization Survey-Teen
(NIS-Teen) data to estimate vaccination coverage. NIS-Teen is a survey used to
estimate the annual vaccination coverage among adolescents in the U.S. 3,13
HPV 16/18 and other high-risk types infection
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Data on the incidence of HPV 16/18 and other high-risk infections were derived
from the literature.

14

That research followed a female cohort aged 15-85 years old

(N=1,610) with negative HPV infections and normal cytological results at the baseline
and every 6 months for an average of 4.1 years. Study found that the incidence of all
HPV high-risk type infections was 5.0 cases/100 woman-years. The incidence of HPV
16 and 18 type infections were 1.0 and 0.7 cases/100 woman-years, respectively.
We derived the progression and regression of incident HPV infection from a
study by Insinga et al. (2007).

15

A cohort of 16-23 years old females (N=2,391) was

followed every 6 months for 4 years. Results for the 12-month HPV 16 type infection
regressed to negative infection, progressed to CIN I, II, and III, were 0.354, 0.105,
0.045, and 0.024, respectively.
LSIL and HSIL
Data on the transition probabilities of SIL were derived through a meta-analysis
of published studies. 16. The conclusion was that the 6-month transition probability of
HSIL to cancer was 0.0037. For the LSIL, the 6-month transition probabilities were
0.074 and 0.036 for the regression rate to normal and the progression rate to HSIL,
respectively. We assumed no prevalent LSIL and HSIL existed in the initial cohort
population.
Cervical cancer
Cervical cancer is classified by three stages: local cervical cancer, regional cervical
cancer, and distant cervical cancer. Data on transition probabilities related to cervical
cancer, including progression rate to a more severe stage, symptom detection, and
stage-specific cancer mortalities, were derived from the literature.

17,18

. Patients

underwent treatment after cancer detections and were defined as cancer survivors.
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Utility
The utility weight of HPV infection is assumed to be 1, as it is asymptomatic. 4.
The quality of life weights for females diagnosed with LSIL, HSIL and local stage
cancers were derived from the published literature.19. In that work, researchers
interviewed 276 females to measure utility scores for HPV vaccination, CIN I-III, and
early cancer stage using EQ5D. Females diagnosed at the regional stage were assumed
to have a quality of life assessments of 0.67.20. Quality of life weight for the distant
cancer stage was assumed to be 0.48, using 25th percentiles for quality of life scores
among 27 females found having genital cancer 21.
Results
Base-case analysis results
We compared costs and effectiveness of interventions involving the patient
reminder and recall system, patient education, provider reminder, school-based vaccine
programs, reducing out-of-pocket costs, and intervention combinations versus current
practice. The parameters of costs and effectiveness used in the base-case and sensitivity
analysis are presented in Table 10. Interventions, except the current practice were
ordered from lowest to highest costs. Under base-case conditions, we found that patient
reminder and recall system was cost-saving, compared with current practice. The cost
of implementing patient reminder and recall systems were lower than current practice
and yielded better QALYs outcome (Table 11). Interventions of both provider reminder
and patient education were dominated by patient reminder and recall system since it
has higher costs but the lower effectiveness than patient reminder and recall system.
The ICER of reducing out-of-pocket costs were $196,164. The school-based vaccine
85

programs were dominated since they have higher costs but lower QALYs than the
intervention combination. The intervention combination was extended dominance since
the ICER of it was greater than reducing out-of-pocket costs.
Sensitivity analysis
Sensitivity analysis was performed to address uncertainties for main input
parameters, including intervention costs, the intervention effectiveness, the HPV
vaccine cost, incidence rates of HPV infections, cervical cancer stage-specific treatment
costs and utility weights. Tornado diagrams of multiple one-way sensitivity analyses
were presented (Figure 9 to 14). We found that intervention effectiveness has a greater
impact on the ICER than intervention costs. When we varied the costs for each HPV
vaccine promotion intervention, patient reminder and recall system remained the most
cost-effective in the majority analysis. When the effectiveness of patient reminder and
recall system was lower than 6%, provider reminder is the most cost-effective
intervention. If the effectiveness of patient education was higher than 19%, patient
education is the most cost-effective intervention. School-based vaccine programs and
intervention combinations are the most cost-effective intervention when its
effectiveness is higher than 21% and 29%, respectively. When we varied the cost of the
HPV vaccine varied in the range of $664 to $814, patient reminder and recall systems
remained the most cost-effective intervention.
Two-way sensitivity analyses were performed which costs and effectiveness of
each intervention were varied simultaneously. The patient reminder and recall system
remained the most cost-effective intervention in the majority analysis. However, if the
cost for the intervention designed to reduce out-of-pocket costs decreased to $211/ per
participant and its effectiveness is higher than 36%, it is more cost-effective than patient
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reminder and recall system. If the cost for the intervention combinations decreased to
$250/ per participant and effectiveness is higher than 42%, it is more cost-effective than
the patient reminder and recall system. We examined the “best-case (the lowest cost
and the highest effectiveness)” and “worst-case (the highest cost and the lowest
effectiveness)” scenarios in the multiple-way sensitivity analysis (Table 12). In the
best-case scenario, the most cost-effective intervention was intervention combinations.
In the worst-case scenario, the most cost-effective was provider reminder. PSA was
performed on the main input parameters using 1000 Monte-Carlo simulations with
samples from defined distribution. Figure 15 displays the cost-effectiveness
acceptability curve (CEAC), which illustrates the probability that the reducing out-ofpocket costs intervention will be cost-effective versus the patient reminder and recall
system for a hypothetical set of decision-maker willingness to pay values. Interventions
which were dominated or extended dominance in the base-case analysis, including
provider reminder, intervention combinations, patient education and school-based
vaccine programs were excluded in the CEAC analysis. If the willingness to pay is
$25,000 per QALY, the probability that reducing out-of-pocket costs will be costeffective relative to the patient reminder and recall system is 0. If the willingness to pay
is $200,000 per QALY, the probability that reducing out-of-pocket costs will be costeffective relative to the patient reminder and recall system is 52.4%.
Discussion
As the HPV vaccine coverage is suboptimal in the U.S., we have put many efforts
into developing interventions to increase vaccine coverage. Resource consequences of
developing HPV vaccine promotion interventions should be included in the evaluation
of HPV vaccination programs. It is also important to determine what types of HPV
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vaccine promotion intervention are most cost-effective in improving health outcomes.
We conducted a CUA to evaluate HPV vaccine promotion interventions of vaccination
programs. To our knowledge, this is the first study that examined alternative HPV
vaccine promotion interventions in the evaluation of HPV vaccination.. The audience
of this study includes health promotion intervention planners and decision-makers who
select the intervention within their resource and budgetary constraints.
We compared 6 HPV vaccine promotion interventions—the patient reminder and
recall system, patient education, provider reminder, school-based vaccine programs,
reducing out-of-pocket costs and intervention combination versus current practice.
Study shows that implementing patient recall and reminder system is the most costeffective intervention of the HPV vaccination programs. Implementing patient
reminder and recall system is cost-saving to the HPV vaccination program, compared
with current practice. The intervention designed to reduce patient out-of-pocket costs
was more effective in improving health outcomes than the patient reminder and recall
system but substantially increased the cost. Decision-makers need to consider the
applicability of interventions (e.g. different population or settings) and budgets for
implementing the interventions to determine which intervention would be justified and
feasible. Social and political issues need to be discussed by stakeholder groups,
including parents, adolescents, pediatricians, school administrators and community
before HPV vaccine promotion interventions are successfully implemented.
To validate our model simulations, we compared our lifetime cost estimates and
QALYs with published researches which also used the Markov model to evaluate the
HPV vaccination program in the U.S. (Table 13).

4,22,23

Our study shows the lifetime

cost estimate ranged from $7,450 to $7,900, depending on the intervention strategies.
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Costs range widely from $600 to $39,000 in the literature and our estimates are within
the range. QALYs estimates in our study ranged from 28.4868 years of current practice
to 28.4959 years of reducing out-of-pocket costs. The result is similar across prior
research that shows the QALYs estimate ranging from 26 to 29 years gained per woman
4,22,23

.

The main limitation of the study is the lack of data sources for some parameters.
The effectiveness of the HPV vaccine completion rate for the school-based vaccine
programs was not available in the literature. We used an alternative outcome HPV
vaccine initiation rate in the base-case analysis. The cost data on both provider
reminders and intervention combinations were not available in the literature. We
applied the cost of interventions intended to increase other immunizations (eg.
influenza or pneumococcal) from the Community Guide reports. Therefore, our model
should be updated when the cost data is available. Secondly, our Markov model does
not take into account the impact of the vaccination on herd immunity, making our
results

conservative. Prior studies using the dynamic transmission model that

accounted for herd immunity effects have shown that ICER for HPV vaccination
program would be even lower. Thirdly, we did not include all of the HPV vaccine
promotion interventions because of the lack of both cost and effectiveness data in the
literature. Interventions include the provider assessment and feedback, vaccination
requirements for school attendance, standing orders and immunization information
systems were excluded from our analysis. Extending our analysis to include those
interventions when data is available is needed.
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Conclusions
A CUA was conducted to assess HPV vaccine promotion interventions of cervical
cancer in the U.S. The study shows that implementing patient recall and reminder
system is the most cost-effective intervention of the HPV vaccination programs.
Compared with current practice, patient recall and reminder system is cost-saving since
the cost is lower and yields a better health outcome. Decision-makers need to consider
the applicability of interventions and budgets for implementing the interventions.
Social and political issues need to be discussed by stakeholder groups before HPV
vaccine promotion interventions are successfully implemented.
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Figure 8. States and allowed transitions of natural history of cervical cancer
Intervention (compared patient reminder and recall system, patient
education, provider reminder, school-based vaccine program, reducing outof-pocket and community-based intervention combination versus current
practice)

Vaccinated

No Vaccinated

Well

HPV infection (16/18 or
other high-risk types)

Low grade SIL

High grade SIL

Undetected / detected
cervical cancer

Cancer death
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Death from other
cause

Table 9. The CHEERS checklist of the study
Section/item
Item Recommendation
No
Title

1

Abstract

2

Background
and objectives

3

Target
population and
subgroups
Setting and
location
Study
perspective
Comparators

4

7

Time horizon

8

Discount rate

9

Choice of
health
outcomes

10

Measurement
of effectiveness

11

Measurement
and valuation
of preference
based outcomes
Estimating
resources and
costs

12

5
6

13

Reported
on page
No
Identify the study as an economic evaluation or 79
use more specific terms such as “costeffectiveness analysis”, and describe the
interventions compared.
Provide a structured summary of objectives,
Abstract
perspective, setting, methods (including study
page
design and inputs), results (including base case
and uncertainty analyses), and conclusions.
Provide an explicit statement of the broader
79
context for the study. Present the study
question and its relevance for health policy or
practice decisions.
Describe characteristics of the base case
80
population and subgroups analyzed, including
why they were chosen.
State relevant aspects of the system(s) in which 80
the decision(s) need(s) to be made.
Describe the perspective of the study and relate 80
this to the costs being evaluated.
Describe the interventions or strategies being
80
compared and state why they were chosen.
State the time horizon(s) over which costs and 80
consequences are being evaluated and say why
appropriate.
Report the choice of discount rate(s) used for
80
costs and outcomes and say why appropriate.
Describe what outcomes were used as the
80
measure(s) of benefit in the evaluation and
their relevance for the type of analysis
performed.
Single study-based estimates: Describe fully
81
the design features of the single effectiveness
study and why the single study was a sufficient
source of clinical effectiveness data.
If applicable, describe the population and
83
methods used to elicit preferences for
outcomes.
Single study-based economic evaluation:
Describe approaches used to estimate resource
use associated with the alternative
interventions. Describe primary or secondary
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81

Currency, price
date, and
conversion

14

Choice of
model

15

Assumptions

16

Analytical
methods

17

Study
parameters

18

Incremental
costs and
outcomes

19

Characterizing
uncertainty

20

Characterizing
heterogeneity

21

research methods for valuing each resource
item in terms of its unit cost. Describe any
adjustments made to approximate to
opportunity costs.
Report the dates of the estimated resource
quantities and unit costs. Describe methods for
adjusting estimated unit costs to the year of
reported costs if necessary. Describe methods
for converting costs into a common currency
base and the exchange rate.
Describe and give reasons for the specific type
of decision analytical model used. Providing a
figure to show model structure is strongly
recommended.
Describe all structural or other assumptions
underpinning the decision-analytical model.
Describe all analytical methods supporting the
evaluation. This could include methods for
dealing with skewed, missing, or censored
data; extrapolation methods; methods for
pooling data; approaches to validate or make
adjustments (such as half cycle corrections) to
a model; and methods for handling population
heterogeneity and uncertainty.
Report the values, ranges, references, and, if
used, probability distributions for all
parameters. Report reasons or sources for
distributions used to represent uncertainty
where appropriate. Providing a table to show
the input values is strongly recommended.
For each intervention, report mean values for
the main categories of estimated costs and
outcomes of interest, as well as mean
differences between the comparator groups. If
applicable, report incremental costeffectiveness ratios.
Model-based economic evaluation: Describe
the effects on the results of uncertainty for all
input parameters, and uncertainty related to the
structure of the model and assumptions.
If applicable, report differences in costs,
outcomes, or cost- effectiveness that can be
explained by variations between subgroups of
patients with different baseline characteristics
or other observed variability in effects that are
not reducible by more information.
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80

80

80
80

93

96

84

NA

Study findings, 22
limitations,
generalizability,
and current
knowledge
Source of
23
funding

Conflicts of
interest

24

Summarize key study findings and describe
how they support the conclusions reached.
Discuss limitations and the generalizability of
the findings and how the findings fit with
current knowledge.
Describe how the study was funded and the
role of the funder in the identification, design,
conduct, and reporting of the analysis.
Describe other non-monetary sources of
support.
Describe any potential for conflict of interest
of study contributors in accordance with
journal policy. In the absence of a journal
policy, we recommend authors comply with
International Committee of Medical Journal
Editors recommendations.
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NA

NA

Table 10. Input values and sources for transition probabilities in the model
Parameter
HPV vaccine coverage increased by HPV promotion interventions
current practice
Patient reminder and recall system
Patient education
Provider reminder
Vaccination programs in school
Reducing out-of-pocket costs
Community-based intervention combination
Intervention cost (2018 USD)
Current practice
Patient reminder and recall system
Patient education
Provider reminder
Vaccination programs in school
Reducing out-of-pocket costs
Intervention combination
Cost
HPV vaccine
Treatment for LSIL
Treatment for HSIL
Treatment for cervical cancer local stage
Treatment for cervical cancer reginal stage
Treatment for cervical cancer distant stage
HPV vaccine
Baseline HPV vaccine coverage in 12 years old females a
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Base-case

Range

Source

+2%
+10%
+7%
+8%
+5%
+28%
+13%

NA
0~25%
0~25%
+8%~+17%
+5%~+41%
+10%~+45%
+2%~+56%

24

$3
$22
$73
$29
$85
$575
$133

0~$6
$2~$33
$37~$90
$8~$62
$43~$128
$40~$724
$63~$313

39

$739
$2,331
$5,165
$38,260
$40,948
$65,585

$664~$814

12,45

38.9%

25–27
28–32
24,28,33
34–36
28,37,38

40,41
39
33
35
39,42,43
44

13,18
13,18
46
46
46
3

Annual probability on HPV vaccination in 13-18 years old females
19-26 years old females
Vaccine efficacy (%)
HPV types 16/18 infection
Incidence of HPV 16 infection
Incidence of HPV 18 infection
Regression to negative HPV 16/18 infection
HPV 16/18 infection progressed to CIN I
HPV 16/18 infection progressed to CIN II
HPV 16/18 infection progressed to CIN III
Proportion of HPV 16/18 infection
HPV other high-risk infection
Incidence of HPV other high-risk infection
Regression to negative HPV other high-risk infection
HPV other high-risk infection progressed to CIN I
HPV other high-risk infection progressed to CIN II
HPV other high-risk infection progressed to CIN III
LSIL
Developing HSIL from LSIL
LSIL regressed to well
HSIL
Prevalence of HSIL in the initial cohort
Developing cervical cancer stage I from HSIL
HSIL regressed to well
HSIL regressed to LSIL
Cervical cancer
Progression from local stage to reginal stage
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0.129
0.026
100.00%

13

0.010
0.007
0.354
0.105
0.045
0.024
0.135

14

0.050
0.403
0.063
0.032
0.004

14

0.071
0.143

16

0
0.007
0.296
0.056

Assumption

0.215

17

13

Assumption
14
15
15
15
15
13

47
47
47
47

16

16,48
48
16

Progression from reginal stage to distant stage
Mortality of local stage in year 1
year 2-3
year 4-20
Mortality of reginal stage in year 1
year 2-3
year 4-20
Mortality of distant stage in year 1
year 2-3
year 4-20
Probability of symptom detection for local stage
Probability of symptom detection for reginal stage
Probability of symptom detection for distant stage
Utility
HPV infection
LSIL
HSIL
Cervical cancer local stage
Cervical cancer reginal stage
Cervical cancer distant stage
Cervical cancer survivor
Discount rate
Markov model cycle length
a: HPV up-to-date rate among 13 years females in 2018
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0.262
0.019
0.017
0.011
0.108
0.090
0.042
0.300
0.210
0.087
0.190
0.600
0.900

17

1.00
0.972
0.970
0.818
0.67
0.48
0.76
0.03
1 year

4

17
17
17
17
17
17
17
17
17
17
17
17

19
19
19
18
18
18

Assumption
Assumption

Table 11. Cost-effectiveness of HPV vaccine promotion interventions
Incremental
Strategya
Cost
cost
QALY(yrs)
7861.14
28.4868
Current practice
7449.56
-411.58
28.4936
Patient reminder and recall system
7491.59
42.03
28.4931
Provider reminder
7615.80
166.24
28.4928
Intervention combinations
7616.16
166.60
28.4942
Patient education
7702.22
86.06
28.4921
School-based vaccine programs
7900.02
450.46
28.4959
Reducing out-of-pocket costs
a: Interventions were ordered from the lowest to the highest cost
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Incremental
Effectiveness
0.0068
-0.0005
-0.0008
0.0006
-0.0021
0.0023

ICER

C/E

Cost-saving
Dominated
Dominated
Extended dominance
Dominated
$196,164

275.96
261.45
262.93
267.29
267.29
270.33
277.23

Figure 9. Tornado diagram of ICER: patient reminder vs. current practice

Figure 10. Tornado diagram of ICER: patient education vs. current practice
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Figure 11. Tornado diagram of ICER: provider reminder vs. current practice

Figure 12. Tornado diagram of ICER: school-based vaccine programs vs. current
practice
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Figure 13. Tornado diagram of ICER: reducing out-of-pocket costs vs. current practice

Figure 14. Tornado diagram of ICER: intervention combinations vs. current practice
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Table 12. Results of the multiple-way sensitivity analysis for HPV vaccine promotion interventions in the CUA
Incremental
Incremental
ICER
Strategya
Cost
cost
QALY(yrs)
Effectiveness
The best-case scenario: the lowest costs and the highest effectiveness of HPV vaccine promotion interventions
7847.69
28.4868
Current practice
7277.34
-570.34
28.4972
0.0104
Cost-saving
Intervention combinations
7288.41
11.07
28.4968
-0.0004
Dominated
Reducing out-of-pocket costs
7301.05
23.71
28.4966
-0.0005
Dominated
School-based vaccine programs
7316.70
39.35
28.4957
-0.0015
Dominated
Patient reminder and recall system
7356.48
79.14
28.4957
-0.0015
Dominated
Patient education
7364.25
86.90
28.4948
-0.0023
Dominated
Provider reminder
The worst-case scenario: the highest costs and the lowest effectiveness of HPV vaccine promotion interventions
7888.04
28.4868
Current practice
7568.06
-319.98
28.4931
0.0063
Cost-saving
Provider reminder
7702.05
133.99
28.4894
-0.0037
Dominated
Patient reminder and recall system
7823.60
255.54
28.4921
-0.0010
Dominated
School-based vaccine programs
7956.23
388.18
28.4894
-0.0037
Dominated
Patient education
8644.80
1076.74
28.4907
-0.0024
Dominated
Intervention combinations
8903.14
1335.08
28.4936
0.0005
Dominated
Reducing out-of-pocket costs
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C/E

275.49
255.37
255.76
256.21
256.77
258.16
258.44
276.90
265.61
270.35
274.59
279.27
303.43
312.46

Table 13. Comparisons with the CEA results between literature using Markov model in evaluating HPV vaccine in the US.
Author
Target
HPV vaccine Results for the economic evaluation on HPV Epidemiology outcomes for
(year)
population
coverage
vaccination
HPV vaccination
assumption
Sanders and 12 years old 70% of vaccine Cost for the standard of care without Averts more than 224,255
Taira (2003) girls through coverage
vaccination: $39,682
cases of HPV, 112,710
4
lifetime
Cost for the standard of care with vaccination: cases of SIL, 3,317 cases of
$39,928
cervical
cancer
when
QALYs for the standard of care without vaccinating the population
vaccination: 27.720 (yrs)
of approximately 1,988,600
QALYs for the standard of care with girls
vaccination: 27.731 (yrs)
ICER between two above strategies
=$22,755/QALY gained
Kulasingam 12 years old 100%
of Cost of screening every 3 years for 18 years old Reduced cervical cancer
and Myers girls through vaccine
females without vaccination: $632
incidence by 82.6% when
(2003) 22
85 years old
coverage
Cost of screening every 2 years for 24 years old vaccinating
the target
females with vaccination: $834
population
LYs of screening every 3 years for 18 years old
females without vaccination: 28.7518 (yrs)
LYs of screening every 2 years for 24 years old
females with vaccination: 28.7563 (yrs)
ICER
between
two
above
strategies=$44,889/LY gained
Goldie et al. 13 years old 100%
of Cost of standard of care without vaccination: Reduced the lifetime risk of
(2004) 23
girls through adolescent
$1,111
cervical cancer by 66%
lifetime
cohort
is
103

successfully
vaccinated

Cost of standard of care with vaccination: when efficacy of HPV
$1,384
vaccine is 100%
QALYs for the standard of care without
vaccination: 25.9815 (yrs)
QALYs for the standard of care with
vaccination: 25.9948 (yrs)
ICER between two above strategies
=$20,600/QALY gained

Abbreviation: ICER, Incremental cost-effectiveness ratio; SIL, Squamous intraepithelial lesions; QALYs, Quality-adjusted-life-years; LYs, Lifeyears
A: Standard of care included routine Pap tests for every 2 years starting at age
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Figure 15. Cost-effectiveness acceptability curve compare reducing out-of-pocket costs
versus patient reminder and recall system
Probability of cost-effective (%)
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CONCLUSION
A total of 56 studies for the HPV vaccine promotion intervention were included
in the study. Intervention approaches used to improve HPV vaccine coverage included
patient reminder and recall systems, patient education, provider assessment and
feedback, provider reminders, reducing out-of-pocket costs, school-based vaccine
programs, vaccination requirements for school attendance, standing orders,
immunization

information

systems

and

multiple

component

interventions

(interventions implemented in combination involved more than two interventions).
Most interventions significantly increased HPV vaccine rates using varied approaches
across populations and settings, and with modest cost. A cost-effectiveness analysis
was conducted to assess those HPV vaccine promotion interventions. We assessed
interventions which their cost and effectiveness are available across literature. We
included patient reminder and recall system, patient education, provider reminders,
reducing patient out-of-pocket costs, school-based vaccine programs, and communitybased intervention combinations in the economic evaluation. We found that patient
reminder and recall system is the most cost-effective HPV vaccine promotion
interventions. The cost per additional individual completed HPV vaccine series (ICER)
was $238. When the intervention effectiveness was measured as the percentage change
of receiving at least one dose HPV vaccine, the ICER for the patient reminder and recall
system was $107. When we incorporated cervical cancer natural history, cost and
quality of life for cervical cancer, patient recall can reminder system is cost-saving since
the cost is lower and yields a better health outcome, compared with current practice.
The study provides evidence-based information to decision-makers about interventions
aimed to improve HPV vaccine coverage.
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APPENDICES
Table 1. Searching keywords
Concepts
human papillomavirus

vaccine

intervention

Key words used fir searching
papillomaviridae/ or
alphapapillomavirus/ or human
papillomavirus 6/ or human
papillomavirus 11/ or human
papillomavirus 16/ or human
papillomavirus 18/ or human
papillomavirus 31/ or
betapapillomavirus/ or
gammapapillomavirus/ or
mupapillomavirus/
(hpv or papillomavirus or
papillomaviridae or alphapapillomavirus
or betapapillomavirus or
mupapillomavirus or genital warts or
epidermodysplasia verruciformis or
condyloma*).ti,ab,kw.
papillomavirus infections/ or warts/ or
condylomata acuminata/ or buschkelowenstein tumor/ or epidermodysplasia
verruciformis/
vaccines/ or viral vaccines/ or
immunization/ or immunization
schedule/ or immunization, secondary/ or
immunotherapy/ or immunotherapy,
active/ or vaccination/ or mass
vaccination/ or immunization programs/
or (vaccin* or immuniz* or
immunis*).ti,ab,kw.
public health/ or school education/ or
Epidemiology/ or prevent/ or preventing/
or prevention/ or protect/ or protects/ or
protecting/ or protection/ or public
health/ or
education/ or program/ or train/ or
training/ or support/ or project/ or
(educat* or program* or
intervent*).ti,ab,kw.
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Table 2:Ovid Medline® search strategy
Provider/Interface
Database
Date searched
Database update
Search
developer(s)
Limit to English
Date Range
Search filter
source

Ovid
Medline®
2017/7/28
Chi-Fang Wu and Helena M. VonVille
Yes
2006-2017
http://libguides.sph.uth.tmc.edu/search_filters/topicsfilters

# Searching key words
vaccines/ or viral vaccines/ or immunization/ or immunization
schedule/ or immunization, secondary/ or immunotherapy/ or
immunotherapy, active/ or vaccination/ or mass vaccination/ or
immunization programs/ or (vaccin* or immuniz* or
1. immunis*).ti,ab,kw.
papillomaviridae/ or alphapapillomavirus/ or human
papillomavirus 6/ or human papillomavirus 11/ or human
papillomavirus 16/ or human papillomavirus 18/ or human
papillomavirus 31/ or betapapillomavirus/ or
2. gammapapillomavirus/ or mupapillomavirus/
(hpv or papillomavirus or papillomaviridae or
alphapapillomavirus or betapapillomavirus or mupapillomavirus
or genital warts or epidermodysplasia verruciformis or
3. condyloma*).ti,ab,kw.
papillomavirus infections/ or warts/ or condylomata acuminata/ or
buschke-lowenstein tumor/ or epidermodysplasia verruciformis/
4.
5. 2 or 3 or 4
6. 1 and 5
papillomavirus vaccines/ or human papillomavirus recombinant
7. vaccine quadrivalent, types 6, 11, 16, 18/
8. 6 or 7
public health/ or school education/ or Epidemiology/ or prevent/
or preventing/ or prevention/ or protect/ or protects/ or protecting/
or protection/ or public health/ or
education/ or program/ or train/ or training/ or support/ or project/
9. or (educat* or program* or intervent*).ti,ab,kw.
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Item
found
275136

21893

38627

24206
43340
10673
6240
11300
1474261

10 8 and 9
11. limit 10 to (english language and yr="2006 - 2017")
(11 and exp united states/) or (11 not (exp africa/ or exp asia/ or
exp australia/ or exp canada/ or exp europe/ or exp south
12. america/))
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3414
3088
1892

Table 3: PubMed search strategy
Provider/Interface
Database
Date searched
Database update
Search developer(s)
Limit to English
Date Range
Search filter source

National Library of Medicine
PubMed
2017/07/31
Chi-Fang Wu and Helena M. VonVille
Yes
2006-2017
http://libguides.sph.uth.tmc.edu/search_filters/topicsfilters

# Searching key words
vaccines[mesh:noexp] OR viral vaccines[mesh:noexp] OR
immunization[mesh:noexp] OR immunization
schedule[mesh:noexp] OR immunization, secondary[mesh:noexp]
OR immunotherapy[mesh:noexp] OR immunotherapy,
active[mesh:noexp] OR vaccination[mesh:noexp] OR mass
vaccination[mesh:noexp] OR immunization programs[mesh:noexp]
1 OR (vaccin*[tiab] OR immuniz*[tiab] OR immunis*[tiab])
papillomaviridae[mesh:noexp] OR
alphapapillomavirus[mesh:noexp] OR human papillomavirus
6[mesh:noexp] OR human papillomavirus 11[mesh:noexp] OR
human papillomavirus 16[mesh:noexp] OR human papillomavirus
18[mesh:noexp] OR human papillomavirus 31[mesh:noexp] OR
betapapillomavirus[mesh:noexp] OR
gammapapillomavirus[mesh:noexp] OR
2 mupapillomavirus[mesh:noexp]
(hpv[tiab] OR papillomavirus[tiab] OR papillomaviridae[tiab] OR
alphapapillomavirus[tiab] OR betapapillomavirus[tiab] OR
mupapillomavirus[tiab] OR genital warts[tiab] OR
3 epidermodysplasia verruciformis[tiab] OR condyloma*[tiab])
papillomavirus infections[mesh:noexp] OR warts[mesh:noexp] OR
condylomata acuminata[mesh:noexp] OR buschke-lowenstein
tumor[mesh:noexp] OR epidermodysplasia
4 verruciformis[mesh:noexp]
5 #2 OR #3 OR #4
6 #1 AND #5
papillomavirus vaccines[mesh:noexp] OR human papillomavirus
7 recombinant vaccine quadrivalent, types 6, 11, 16, 18[mesh:noexp]
8 #6 OR #7
public health[mesh:noexp] OR school education[mesh:noexp] OR
Epidemiology[mesh:noexp] OR prevent[mesh:noexp] OR
preventing[mesh:noexp] OR prevention[mesh:noexp] OR
9 protect[mesh:noexp] OR protects[mesh:noexp] OR
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Item
found
405181

27400

45495

28500

54252
10713
5765
11291
658273

protecting[mesh:noexp] OR protection[mesh:noexp] OR public
health[mesh:noexp] OR education[mesh:noexp] OR
program[mesh:noexp] OR train[mesh:noexp] OR
training[mesh:noexp] OR support[mesh:noexp] OR
project[mesh:noexp] OR intervention OR (educat *[tiab] OR
program *[tiab] OR intervent *[tiab])
10 #8 AND #9
11 #10 AND (english[la] AND 2006:2017[dp])
(#11 AND (north america[mesh:noexp] OR united states[mesh]))
OR (#11 NOT (africa[mesh] OR asia[mesh] OR australia[mesh] OR
12 canada[mesh] OR europe[mesh] OR south america[mesh]))
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697
617
422
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